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ABSTRACT 
 
 
The amyloid β-protein (Aβ) is the main component of Alzheimer’s disease (AD)-related senile 
plaques. In the human brain Aβ-deposition occurs in a hierarchical sequence in which different areas 
of the brain become involved. It is not clear whether this sequence shows the time course of Aβ-
deposition or just different pathology in different individuals. Although Aβ is associated with the 
development of AD it has not been shown which forms of Aβ induce neurodegeneration in vivo, 
which types of neurons are vulnerable and whether Aβ-induced neurodegeneration increases with the 
progression of Aβ-pathology.  To address these questions, DiI-crystals were implanted into the left 
frontocentral cortex of APP23 transgenic mice overexpressing mutant human APP and of wild-type 
littermates. In parallel, immunohistochemistry for Aβ-plaque detection was performed in 3-, 5-, 11-, 
15- and 25-month-old APP23 mice and wild-type littermates. Traced commissural neurons in layer III 
of the right frontocentral cortex were quantified in 3-, 5-, 11-, and 15-month-old mice. Three different 
types of commissural neurons were traced. At 3 months of age no differences in the number of labeled 
commissural neurons were seen in APP23 mice compared to wild-type mice. A selective reduction of 
the heavily ramified type of neurons was observed in APP23 mice compared to wild-type animals at 5, 
11, and 15 months of age, starting with the deposition of Aβ-plaques occurred in the frontocentral 
cortex at 5 months of age. The other two types of commissural neurons did not show alterations in 5- 
and 11-month animals. At 15 months of age, the number of traced sparsely ramified pyramidal neurons 
was reduced in addition to that of the heavily ramified neurons in APP23 mice compared with wild-
type mice. At this point in time Aβ-deposits were seen in the neo- and allocortex as well as in the basal 
ganglia and the thalamus. At 25 months of age Aβ-deposits were also seen at the brainstem. In 
summary, the results show that 1) Aβ-deposition in APP23 mice follows a similar sequence as in 
human brain, in which the different areas become step-by-step involved in β-amyloidosis, 2) this step-
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by-step regional involvement represents the time course of Aβ-deposition in the brain, and 3) 
Aβ, thereby, induces progressive degeneration of distinct types of commissural neurons. Degeneration 
of the most vulnerable neurons starts in parallel with the occurrence of the first fibrillar Aβ deposits in 
the neocortex. The selective vulnerability of different types of neurons to Aβ is presumably related to 
the complexity of their dendritic morphology. In so doing, these results support Aβ to be the major 
therapeutic target for AD treatment in pre-clinical as well as in late stages of the disease.
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1. INTRODUCTION 
 
 
In 1907 the German psychiatrist and neuropathologist Dr. Alois Alzheimer described changes in 
the brain of a 55-year-old woman dying after a 4-year history of progressive dementia (Alzheimer, 
1907). The leading symptoms were: progressive memory impairment, disordered cognitive function, 
altered behavior including paranoia, delusions, loss of social appropriateness, and a progressive 
decline in language function. In his report, Alzheimer demonstrated neurofibrillary tangles using the 
Bielschowsky silver impregnation method and he also observed cortical senile plaques (Alzheimer, 
1907), already described 15 years earlier by Blocq and Marinesco (Blocq and Marinesco, 1892). This 
was the first reported case of a disease which is today known as Alzheimer’s disease (AD).   
 
1.1. Alzheimer type dementia 
 
AD is a neurodegenerative disorder, which is clinically characterized by progressive cognitive 
decline finally leading to the full-blown picture of dementia (Duyckaerts and Dickson, 2003). AD is 
the most common cause of dementia and represents 50-70% of all dementias (Lamy et al., 1989; Ferri 
et al., 2005).  
The prevalence of dementia and AD, which is the number of cases in a population at given point 
in time, increases when comparing this parameter in different age groups with advancing age. Between 
65- to 69-year-old individuals the prevalence of dementia is approximately 1%. It duplicates with each 
subsequent 5-year interval. Over 85 years of age, the prevalence varies between 20%-50% (Lamy et 
al., 1989). The incidence, which is the number of newly diagnosed cases in a given time interval, also 
increases dramatically with advancing age when comparing this parameter in different age groups. 
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From 70 to 80 years of age, the number of new cases increases more than 1%. Above 80 years of age, 
the number increases to 2% (Knopman, 2003). 
Cognitive deficits in AD are characterized by deficits in learning and retaining new information 
(Storandt et al., 1984; Knopman and Ryberg, 1989; Welsh et al., 1991; Petersen et al., 1994; Grober 
and Kawas, 1997).  Problems in word finding and loss of conversational skills are the most relevant 
language deficits related to the disease (Knopman, 2003). The patients show deficits in spatial ability, 
orientation and in reasoning or handling complex tasks, alterations in mood or behavior, and in basic 
activities of daily living that characterize the disease (Knopman, 2003).  
The major risk factors for AD are advanced age, a family history of dementia and presence of an 
apolipoprotein E (ApoE) ε4 allele (Heston et al., 1981; Corder et al., 1993; Mayeux et al., 1995; 
Lautenschlager et al., 1996). Low educational achievement increases the risk of developing dementia 
by 2- to 3- fold (Zhang et al., 1990; Friedland, 1993; Katzman, 1993; Stern et al., 1994; Cobb et al., 
1995; Ott et al., 1995; Stern et al., 1995; Callahan et al., 1996). Cardiovascular disease (Elias et al., 
1993; Hofman et al., 1997; Clarke et al., 1998) and elevated serum homocysteine has also been 
associated with dementia although the biological link between homocysteine and AD has not been 
clarified so far (Clarke et al., 1998; McCaddon et al., 1998; Kalmijn et al., 1999; Seshadri et al., 2002). 
Possible protective factors are active life style, low cholesterol levels, education, and the use of 
estrogen and non-steroidal anti-inflammatory drugs (Knopman, 2003). 
AD is morphologically characterized by cerebral atrophy, i.e. loss of brain weight and volume, 
thickness and length of the cortical ribbon and ventricular dilatation (Duyckaerts and Dickson, 2003). 
The degree of cortical atrophy varies and seems to correlate with cognitive decline (Mouton et al., 
1998). 
Microscopically, senile plaques, intracellular neurofibrillary tangles (NFT) and vascular 
amyloid deposits are the hallmark of AD (Alzheimer, 1907; Masters et al., 1985a; Braak and Braak, 
1991b; Dickson, 1997; Esiri et al., 1997; Duyckaerts and Dickson, 2003). In addition, neuronal and 
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synaptic loss is also associated with AD (Terry et al., 1981; Braak and Braak, 1991b; Duyckaerts and 
Dickson, 2003). An early morphological correlative for neuronal loss is corpus callosum atrophy 
which can be detected in living patients by imaging techniques (Weis et al., 1991; Yamauchi et al., 
1993; Hampel et al., 1998). 
 
1.2.  Amyloid-β protein deposition  
 
Amyloid deposits consist of extracellular insoluble fibrillar proteins or peptides with a high 
content of β-pleated sheet secondary structure and show a characteristic red-green birefringence in 
Congo red-stained sections (Virchow, 1854, 1855). The aggregated protein in the senile plaques and 
vascular amyloid deposits in brain of AD-patients is the amyloid β-protein (Aβ) (Glenner and Wong, 
1984; Masters et al., 1985b).  
 
1.2.1. Aβ production and degradation 
 
Aβ is a 40-42 amino acid peptide of 4 KDa. It is derived from the amyloid precursor protein 
(APP) by sequential proteolytic cleavage (Kang et al., 1987; Haass et al., 1992). APP is an internal 
type I membrane glycoprotein. It has a large amino terminal extracellular/luminar domain (ectomain) 
and a short cytoplasmic tail. APP is expressed as three alternatively spliced isoforms: APP695 
(neuronal form), and APP770/751 isoforms (peripheral and glial isoforms) (Kang et al., 1987; Dyrks et 
al., 1988; Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988). 
APP can be metabolized by two pathways (fig. 1) (Haass et al., 1992): The non-amyloidogenic 
pathway and the amyloidogenic pathway. The non-amyloidogenic pathway is characterized by α-
secretase cleavage of APP within the Aβ domain (between residues K16 and L17 of Aβ). This 
cleavage results in the release of a large soluble N-terminal fragment (APPSα) into the lumen of the 
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organelles or into the extracellular space and the retention of α-C-terminal fragment (α-CTF) in the 
membrane. Subsequently, γ-secretase complex (a multimeric protein complex that includes presenilin 
(PS)-1 or PS2, nicastrin, anterior pharynx defective protein (APH)-1 and presenilin enhancer protein 
(PEN)-2) cleavages α-CTF within the transmembrane domain generating an N-terminal truncated Aβ 
(p3) and APP intracellular domain (AICD) (Cao and Sudhof, 2001; Cupers et al., 2001; Kimberly et 
al., 2001). On the other hand, the amyloidogenic pathway generates a soluble N-terminal fragment 
(APPSβ) and a C-terminal fragment (β-CTF) in the membrane by β-secretase cleavage (between 
residues M671 and N672 of APP) generating the N-terminus of Aβ (Vassar et al., 1999). Subsequent 
cleavage by γ-secretase complex produces Aβ and AICD (Haass et al., 1992).   
 
In healthy brains secreted Aβ is catabolized by astrocytes (Koistinaho et al., 2004). Apparently, 
Aβ binds to ApoE and such Aβ-ApoE complexes are taken up by astrocytes (Koistinaho et al., 2004) 
and subsequently become enzymatically degraded by neprilysin, insulin degrading enzyme and/or 
endothelin-degrading enzyme (Iwata et al., 2000; Eckman et al., 2001; Miller et al., 2003). Since ApoE 
is also involved in the formation of newly-form plaques (Thal et al., 2005) other clearance mechanisms 
have been investigated. Drainage of extracellular Aβ via perivascular channels has also been shown to 
be a significant mechanism for clearing Aβ from the brain, especially for ApoE-Aβ complexes (Weller 
et al., 1998; Thal et al., 2006b).   
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Figure 1: APP metabolism. A: Schematic representation of APP within the membrane. 
Aβ peptide location within APP is enlarged. α-, β- and γ-secretase cleavage sites are 
indicated. There is a minor cleavage site of β-secretase at 11 amino acid (schematic 
representation modified from (Thal et al., 2006a) B: Amyloidogenic and non-
amyloidogenic processing of Aβ. The non-amyloidogenic processing of APP by α- and 
γ-cleavage results in the generation of APPSα, p3 and AICD. The amyloidogenic 
processing of APP by β- and γ-secretases cleavage produces APPSβ, Aβ and AICD 
(schematic representation modified from (Vetrivel and Thinakaran, 2006). 
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1.2.2. Pathological accumulation of Aβ 
 
Under pathological conditions Aβ accumulates in the brain. Monomeric Aβ aggregates to 
oligomers, protofibrils and finally to amyloid fibrils. A prerequisite for Aβ aggregation is the increase 
of Aβ concentration (Masters and Beyreuther, 2003). This increase may be due to increase of Aβ 
production or due to reduction of Aβ clearance. In familiar AD, mutations in the APP gene or in the 
PS1/PS2 genes lead to an increased production of Aβ (Hardy, 1997; Bertram and Tanzi, 2003; Masters 
and Beyreuther, 2003). However, in sporadic AD no increase in Aβ-production has been detected but a 
reduction of Aβ degradation (Schenk et al., 1999; Iwata et al., 2000; Masters and Beyreuther, 2003; 
Miller et al., 2003; Koistinaho et al., 2004).  
Mutations that modify the amino acid sequence of the Aβ-protein modulate its tendency to 
form insoluble protofibrils and fibrils (Nilsberth et al., 2001; Morimoto et al., 2004). Both, intracellular 
and extracellular aggregates of Aβ seem to be neurotoxic (Vidal et al., 1999; Wirths et al., 2001; 
Takahashi et al., 2004; Kokubo et al., 2005a; McGowan et al., 2005; Lord et al., 2006) but not 
monomeric Aβ (Pike et al., 1991). However, consecutive aggregation of Aβ monomers leads to 
soluble Aβ oligomers called Aβ derived diffusible ligands (ADDLs). Intracellular (Takahashi et al., 
2004) and extracellular ADDLs are neurotoxic (Kayed et al., 2003 ; Kim et al., 2003; Lacor et al., 
2004). A recent study in Tg2576 mice shows that extracellular accumulation of soluble 56KDa Aβ1-42 
assemblies (Aβ*56) can be responsible for the memory deficits prior to amyloid deposition in these 
mice (Lesne et al., 2006).  
Aβ fibrils, derived from ADDLs appear to induce degeneration of neurites and neurons and 
result in the development of senile plaques (Calhoun et al., 1998; Schmitz et al., 2004; Tsai et al., 
2004). Although recent publications indicate an involvement of ADDLs in early Aβ-induced 
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neurotoxicity, further studies are necessary to clarify the possible role of ADDLs in early degeneration 
of neurons and to identify which neuronal compartments may be critical for Aβ-induced neurotoxicity. 
 
1.2.3. Amyloid deposits 
 
 Senile plaques differ in their composition, both in terms of the type of Aβ peptides deposited 
and in terms of other proteins additionally found in Aβ-plaques (Thal et al., 2006a). The two major 
forms of monomeric Aβ are: Aβ1-40 and Aβ1-42 (Glenner and Wong, 1984; Masters et al., 1985b; 
Iwatsubo et al., 1994) representing a 40 and 42 amino acid peptide, respectively. In addition to Aβ1-40 
and Aβ1-42, N-terminal truncated forms of Aβ were also seen in Aβ-plaques. The most common forms 
of N-terminal truncated Aβ peptides are: Aβ3-40/42, Aβ11-40/42 and p3 (Aβ17-40-42) (Saido et al., 1995; 
Saido et al., 1996). Other proteins occurring in senile plaques are the ApoE, α2-macroglobulin, 
interleukin 1α, interleukin 6, components of the complement system, α2-macroglobulin receptor/low 
density lipoprotein receptor-related protein and collageneous Alzheimer amyloid component/collagen  
XXV (Griffin et al., 1989; McGeer et al., 1989; Namba et al., 1991; Strauss et al., 1992; Rebeck et al., 
1993; Thal et al., 1997; Hashimoto et al., 2002). 
 
1.2.3.1.Classification of senile plaques 
 
According to the varying protein composition and the morphology of the plaques, different 
types can be distinguished in the human brain (Table 1) (Duyckaerts and Dickson, 2003; Thal et al., 
2006a).  
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    Table 1. Summary of different types of Aβ-plaques (from (Thal et al., 2006a). 
Plaque type Morphological determination 
1. Diffuse plaque  a) Sharply delineated Aβ42-positive diffuse plaque not detectable with antibodies 
raised against N-terminal epitopes of Aβ. These plaques also exhibit apoE very 
often. 
  b) Fleecy amyloid: III-bordered clouds of Aβ42-positive diffuse plaque not 
detectable with antibodies raised against N-terminal epitopes of Aβ. These plaques 
also exhibit apoE very often. 
  c) Sharply delineated ApoE-negative diffuse plaques exhibiting N-terminal 
epitopes of Aβ. 
  d) Diffuse plaque containing apoE and exhibiting N-terminal epitopes of Aβ. 
  
e) Diffuse "APP-type" neuritic plaque = Diffuse plaque with APP-positive 
dystrophic neurites 
  
f) Diffuse "PHF-type" neuritic plaque = Diffuse plaque with neurofibrillary 
material in dystrophic neurites. 
  
g) Diffuse "a-synuclein-type" neuritic plaques = Diffuse neuritic plaques 
containing a-synuclein-positive dystrophic neurites. This type of diffuse plaque is 
restricted to AD cases with combined Parkinson’s disease. (=Lewy-Plaque). 
2. Subpial band-like Aβ  Sharply-delineated, evenly distributed band-like Aβ within the subpial portion of 
the molecular layer of the temporal and entorhinal cortex. 
3. Lake-like amyloid  Sharply delineated, evenly distributed Aβ-deposits within the parvopyramidal layer 
of the presubicular region; containing neuronal perikarya of normal appearance. 
4. Cored plaque                                       
(=Classical Plaque) 
a) Sharply delineated Aβ-deposits with an amyloid core in the center surrounded 
by a corona of diffuse Aβ-deposits. Between the core and the corona is a small gap 
without Aβ. 
  
b) Cored "APP-type" neuritic plaque = Cored plaque with APP-positive dystrophic 
neurites. 
  
c) Cored "PHF-type" neuritic plaque = Cored plaque with neurofibrillary material 
in dystrophic neurites. 
  d) Cored "α-synuclein-type" neuritic plaques = Cored neuritic plaques containing 
α-synuclein-positive dystrophic neurites. This type of cored plaque is restricted to 
AD cases with combined Parkinson’s disease. 
5. Core-only plaque             
(=burned-out plaque                    
or compact plaque) 
Pure, sharply delineated amyloid cores without associated diffuse Aβ-deposits. 
6. White matter plaque  a) Diffuse type: Sharply delineated, evenly distributed Aβ-deposits within the 
white matter. 
  b) Globular type: Sharply delineated Aβ-deposits in the white matter containing 
globular aggregates of Aβ. 
7. Cotton wool plaque Sharply delineated evenly distributed Aβ-deposits in roundish, cotton wool-like 
amyloid plaques without amyloid core and without neuritic changes. Predominance 
of this plaque type is a characteristic feature for a subset of familial AD cases 
harbouring a presenilin 1 mutation. 
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Figure 2: Amyloid deposits. Diffuse (A) and classical (B) plaques are the most common forms of Aβ-
deposits in AD. They are clearly distinguished morphologically. A: Diffuse plaques consist of non-
compact Aβ-deposits and represent the first type of plaques seen in the human brain. B: Classical plaques 
are characterized by a compact amyloid cored and a surrounding halo of diffuse Aβ representing the 
“mature” form of senile plaques. 
 
Diffuse plaques are characterized by non-compact deposits (Fig. 2A). The size varies from a 
few microns to more than a hundred microns in diameter and they exhibit irregular contours. In the 
absence of neuritic changes different types of diffuse plaques can be distinguished by the presence of 
full length or N-terminal truncated Aβ-peptides and ApoE.  Neuritic changes in diffuse neuritic 
plaques are classified according to the proteins seen in the dystrophic neurites: APP, PHF and α-
synuclein (Wang and Munoz, 1995; Thal et al., 2006a).  Diffuse plaques are frequently seen in elderly 
non-demented individuals. Thereby, non-neuritic diffuse plaques are the first type of plaques seen in 
the brain during the evolution of AD-related Aβ-deposition. They are discussed to represent the 
earliest stage of plaque formation (Delaere et al., 1990). 
Cored plaques, synonymous with classical plaques, are clearly distinguished from diffuse 
plaques by their morphology (Fig. 2B). Cored plaques are characterized by an amyloid core in the 
center surrounded by a corona of diffuse Aβ-deposits. Dystrophic neurites positive for APP, PHF, and 
α-synuclein classify subtypes of cored plaques into APP-type, PHF-type, and α-synuclein-type 
plaques, respectively. Core-only plaques are represented by a sharply delineated amyloid core without 
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any surrounded corona. Cored and cored neuritic plaques may represent “mature” forms of plaques 
that develop from diffuse plaques and occur in late stages whereas diffuse plaques occur in all stages 
of Aβ-deposition (Masters et al., 1985b; Griffin et al., 1995; Thal et al., 2000b). 
Other types of plaques have been also described in the brain: Subpial band-like amyloid, i. e. 
sharply delineated evenly distributed band-like deposits of Aβ within the subpial portion of the 
neocortical molecular layer (Braak and Braak, 1991a, 1991b); lake-like amyloid, i. e. sharply 
delineated, evenly distributed Aβ-deposits (Kalus et al., 1989; Wisniewski et al., 1998); Fleecy 
amyloid, i. e. cloud-like Aβ deposits diffusely distributed in the internal entorhinal layers (Thal et al., 
1999); White matter plaques; and cotton wool plaques, i. e. sharply delineated, evenly distributed Aβ 
deposits in roundish, cotton wool-like amyloid plaques without amyloid core and without neuritic 
changes (for review see (Thal et al., 2006a).  
 
1.2.3.1. Cerebral amyloid angiopathy 
 
In addition to senile plaques, deposition of Aβ is also seen in the walls of cerebral blood vessels 
(Scholz, 1938; Glenner and Wong, 1984). It is known as cerebral amyloid angiopathy (CAA). 
Although CAA may occur independently of AD, it is seen approximately in 80-100% of all AD cases, 
particularly in elderly individuals. CAA is a common cause of cerebral hemorrhage in aged individuals 
(Vinters and Gilbert, 1983). Mutations in the APP gene can lead to CAA with hemorrhage (hereditary 
CAA with hemorrhage of the Dutch type) (Roos et al., 1991). Aβ deposits are mainly located in small 
arteries of the leptomeniges and the cerebral cortex. Factors that influence the balance between 
parenchymal and vascular Aβ-deposition are not fully understood but it seems that ApoE as well as the 
balance of Aβ1-40/Aβ1-42 play an important role for cerebrovascular deposition of Aβ (Olichney et al., 
2000; Thal et al., 2002c; Herzig et al., 2004). The role of ApoE in vascular Aβ-deposition is supported 
by the finding of the presumable involvement of ApoE in the perivascular clearance of Aβ (Thal et al., 
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2006b). Aβ40 represents the major Aβ-protein within vascular Aβ-deposition, in contrast to senile 
plaques where Aβ42 is the major Aβ-form (Gowing et al., 1994). 
 
1.2.3.2. Amyloid deposition in the aging brain and AD 
 
Aβ deposits can be found both in the aging brain and in AD. In non-demented elderly people, 
AD-related Aβ-deposits are restricted to distinct predilection sites. On the other hand, Aβ-deposits are 
seen in numerous areas of the brain in AD patients (Arnold et al., 1991; Braak and Braak, 1991b; 
Bancher et al., 1993; Aging, 1997; Thal et al., 2002a; Thal et al., 2006a). The deposition of Aβ in the 
non-demented and in the AD brain shows a sequence in which the areas of the brain become step-by-
step involved in Aβ-deposition. Five phases of Aβ deposition can be distinguished (Thal et al., 2002a) 
(Fig. 3). In the first phase diffuse Aβ-plaques are found exclusively in the neocortex in small groups in 
layers II, III, IV, and V. The second phase is characterized by additional Aβ-deposits in allocortical 
brain regions, i. e.  in the entorhinal region, CA1, and the cingulate cortex. Subcortical areas become 
involved in phase 3. Aβ-deposits occur in the diencephalic nuclei, the striatum, and the cholinergic 
nuclei of the basal forebrain. A normal aging brain can show phases 1 to 3. Further brain regions are 
usually free of Aβ-deposits in non-demented individuals (Thal et al., 2002a). 
The involvement of further brain regions is most frequently accompanied with the occurrence of 
cognitive deficits. In phase 4 several brain stem nuclei exhibit senile plaques as well. The inferior 
olivary nucleus, the reticular formation of the medulla oblongata, substantia nigra, CA4, the central 
grey of the midbrain, the colliculi superiors and inferiors, and the red nucleus frequently exhibit Aβ-
deposits. Finally, phase 5 is characterized by cerebellar Aβ-deposition. Additionally, the reticular 
formation of the pons, the pontine nuclei, the central and dorsal raphe nuclei, the locus coeruleus, the 
parabrachial nuclei and the reticulotegmental nucleus of the pons become involved in β-amyloidosis in 
this phases as well (Thal et al., 2002a). These phases are the results of a cross-sectional study of 
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human autopsy brains. Although it is tempting to speculate that they represent the time course of Aβ-
deposition, it cannot be excluded that they may show just different pathologies in different individuals. 
 
Phase 1 Phase 2 Phase 3
Phase 4 Phase 5
 
Figure 3: Phases of Aβ-deposition in the human brain. Phase 1 is characterized by neocortical Aβ-deposits. An 
additional allocortical involvement characterizes phase 2. Phase 3 exhibits additional Aβ-deposits in the 
diencephalon, and the basal ganglia. Phase 1-3 represent the pre-clinical stages of the disease. Clinical stages are 
characterized by additional involvement of the midbrain and the lower brain stem in phase 4. In phase 5, Aβ 
deposits also occur in the pons and the cerebellum. Newly involved brain areas are marked in red (from (Thal et al., 
2004).   
  
 
1.3. Neurofibrillary pathology 
 
Neurofibrillary pathology (NFP) is the second major histopathological hallmark of AD and 
includes NFT, neuropil threads and dystrophic neurites in neuritic plaques (Fig. 4). 
NFT are argyrophilic fibrils in the perikarya and proximal dendrites of neurons (Alzheimer 
1907). The major structural component is the tau protein (Grundke-Iqbal et al., 1986; Kosik et al., 
1986), a protein that binds to microtubules in the non-phosphorylated state and regulates the axonal 
transport (Mandelkow and Mandelkow, 1998). However, abnormal phosphorylation of tau results in a 
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disassembly of normal microtubules, leading to the formation of paired helical filaments and finally, 
NFTs (Mandelkow and Mandelkow, 1998).  
 
A B C
 
Figure 4: Neurofibrillary pathology: Neurofibrillary tangles (A), neuropil threads (B) and 
dystrophic neurites (C) of neuritic plaques represent the neurofibrillar pathology in AD. 
 
Neuropil threads are fibrillary aggregates of abnormal phosphorylated tau within dendrites 
(Braak and Braak, 1991b). 
The term neuritic plaque summarizes diffuse and cored plaques which exhibit dystrophic 
neurites (Braak and Braak, 1991b; Thal et al., 2006a). 
  
1.3.1. Staging of neurofibrillary pathology 
 
Similar to Aβ deposits, NFP also occurs frequently in normal aging. In these individuals NFP is 
restricted to entorhinal and limbic areas in non-demented elderly. The development of NFP in the brain 
follows a characteristic sequence in which the different areas of the brain become hierarchically 
involved. This sequence is divided in six stages, i.e. the Braak-stages (Fig. 5) (Braak and Braak, 
1991b). The stages I and II are characterized by a mild to severe alteration of the transentorhinal region 
and the entorhinal cortex (Entorhinal stages I-II). Stages III-IV represent the limbic stages. In addition 
to the transentorhinal and entorhinal region, there is an involvement of the Ammon’s horn and an 
expansion into the gyrus parahippocampalis. Finally, stage V-VI, show further expansion in the 
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isocortical parts of the brain (Braak and Braak, 1991b). Stages IV-VI are frequently associated with 
cognitive decline (Thal et al., 2002a). Similar to the phases of Aβ-deposition, the Braak-stages are the 
result of cross-sectional studies, and it is not clear whether the hierarchical degeneration of neurons 
represents the time course of the disease progression or just different pathologies in different 
individuals. However, the Braak stages correlate with the phases of Aβ-deposition (Thal et al., 2002a). 
 
 
Figure 5: Distribution of the neurofibrillary pathology in human brain is divided in six stages. Stage I-
II showed NFP within the transentorhinal and entorhinal regions. Severe involvement of the entorhinal 
and transentorhinal pre-α layers as well as NFP in the hippocampus and other limbic areas characterize 
stages III-IV.  Finally, additional isocortical NFP characterizes stage V-VI (from (Braak and Braak, 
1991b).  
 
 
1.4. Neuronal loss and synaptic loss in AD 
 
Neuronal loss is well documented in AD (Duyckaerts and Dickson, 2003). In the hippocampus 
the density of neurons decreases up to 57% and is highly correlated with the expansion of NFT 
pathology (Ball, 1977). Since AD is a slowly progressive neurodegenerative disorder, only a few cells 
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undergo apoptosis at a given point in time as seen in a cross sectional autopsy study by quantification 
of  caspase 3 positive neurons (Stadelmann et al., 1999). Multiple studies indicate that caspases are 
involved in AD related neuronal death (Mattson, 2000; Chan et al., 2002; Haughey et al., 2002). 
Vulnerable neuronal populations differ in normal aging and AD (Braak and Braak, 1991b; Morrison 
and Hof, 1997). While the hilus of the dentate gyrus and subiculum show neuronal loss in normal 
aging, the CA1 region exhibits severe neuronal loss mainly in AD patients (West, 1993; West et al., 
1994). In the entorhinal cortex neuronal loss may reach 90% in advanced AD cases. In the isocortex a 
large number of neurons degenerate (Terry et al., 1981; Terry et al., 1987). Pyramidal cells in layers 
III, mainly involved in corticocortical connections, and in layers V are most vulnerable in AD patients 
(Alzheimer, 1907; Terry et al., 1981; Braak and Braak, 1991b; Duyckaerts and Dickson, 2003). In 
Down-syndrome patients, i. e.  trisomy of the chromosome 21 resulting in the overexpression of APP, 
the number of neurons in layer III and V in the frontal neocortex is reduced as well (Davidoff, 1928). 
Moreover, a region-specific reduction of corpus callosum is seen in AD patients indicating the 
degeneration of commissural fibers (Hampel et al., 1998). Magnetic resonance imaging based corpus 
callosum measurements, thus, may reflect the specific loss of large pyramidal neurons in the cortical 
layers III and V of the frontal and parieto-occipital association areas (Hampel et al., 1998). In so doing, 
there is a selective vulnerability of distinct types of neurons in AD. Synaptic and dendritic loss has 
been described in the hippocampus and in neocortex of AD patients (de Ruiter and Uylings, 1987; 
Catala et al., 1988; Scheff et al., 1990). The decrease of cortical synaptic density is reflected by 
changes in the presynaptic marker synaptophysin and correlates with cognitive decline in AD patients 
(DeKosky et al., 1996).  
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1.5. Transgenic mouse  models  for Alzheimer’s disease 
 
Mice expressing pathogenic mutations of human genes have become a very powerful tool for 
biomedical research and drug discovery. The identification of familiar AD-linked mutation in APP, led 
to the generation of different mouse models overexpressing human mutant and non-mutant APP. 
Today, there are more than 40 different types of APP-transgenic mice available and more than 100 
transgenic mice expressing mutation in other genes related with AD (APOE, BACE, PS1, PS2, and 
tau). The development of transgenic mice carrying different mutations and/or the use of different 
promoters results in mice with various phenotypes. These different types of mice allow the analysis of 
different aspects of Aβ and AD-related pathology. A summary presenting the most important mouse 
models is provided in table 2. 
The first APP transgenic mouse model showing significant amyloid pathology was published in 
1995 (Games et al., 1995). The expression of human APP (hAPP) with the Indiana-mutation is driven 
by the platelet derived growth factor-β (PDGF-β) promoter (PDAPP mouse). Mutant APP expression 
in PDAPP mice is approximately 10-fold higher than the endogenous APP levels. First plaques are 
observed at 6 to 9 months of age in the hippocampus and cerebral cortex, and both the number and the 
density of plaques increase with the age. Phosphorylated neurofilament immunoreactive dystrophic 
neurites are detected in the rim of plaques at 10 to 12 months of age, while phosphorylated tau-
immunoreactive dystrophic neurites are observed after 14 months of age (Masliah et al., 2001). The 
dystrophic plaque neurites do not contain filamentous tau, NFT is not observed. Although there is a 
significant amyloid deposition, with decreased synaptic and dendritic densities in PDAPP mice, no 
neuronal loss has been described in these mice (Irizarry et al., 1997; Wu et al., 2004). PDAPP mice 
have both age-independent and age-dependent memory deficits. Deficits in the spatial discrimination 
tests are age-independent and began prior to amyloid deposition (Dodart et al., 1999). On the other 
hand, amyloid load correlates with an age-dependent decrease in spontaneous object-recognition 
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performance (Dodart et al., 1999) and deficits in spatial learning in the Morris water maze from 13 
months of age (Chen et al., 2000).   
 
Table 2. Summary of the most relevant APP transgenic mice.  
Transgenic line Transgene/ 
Promoter 
Behavioural 
phenotypes 
Neurological characteristic Deficits References 
PDAPP Minigene encoding codon 
717 V to F 
mutation/modified hAPP 
introns 6, 7, 8 in construct 
resulted in expression of 
770, 751 and 695 isoforms 
of human APP/PDGF-β 
promoter. 
Significant impairment on a 
variety of different learning 
and memory tests. Age-
independent and age 
dependent memory deficits. 
Aβ deposits, neuritic plaques, 
synaptic loss, astrocytosis and 
microgliosis. 
No NFT or 
neuronal loss 
(Games et 
al., 1995)  
APPSWE 
(2576) 
Human AP695  
cDNA with 
KM670/671NL/ 
hamster prion protein gene 
promoter 
Memory deficits seen in 9-
10 month old tg mice. 
Aβ deposits at 9-12 months. Gliosis, 
dystrophic neurites containing 
phosphorylated tau. Localized 
neurons and synapse loss. 
No NFTs. Aβ 
peptide may be 
modified/processed 
differently to those 
in AD 
(Hsiao et al., 
1996)  
APP23 APP751Swedish/ murine 
Thy-1.2 promoter 
Learning impairment in 
Morris water maze and a 
passive avoidance paradigm 
7x over expression of APP mRNA. 
Aβ deposits at 6 months, by 24 
months in neocortex and 
hippocampus. Inflammation, neuritic 
and synaptic degeneration and tau 
hyperphosphorylation. Evidence for 
CAA. 
No NFTs. (Sturchler-
Pierrat et al., 
1997) 
APPLondon 
V717I 
Human APP695 cDNA 
with V717I/ 
mouse Thy-1 gene. The 
thymus specific regulatory 
elements in intron 3 are 
thereby deleted, making 
the resulting promoter 
"neuron-specific". 
Decreased exploration, 
increased neophobicity, 
increased male aggressivity. 
Amyloid plaques and 
cerebrovascular 
angiopathy - onset 10-12 months, 
cholinergic fiber distortion. 
No NFTs. (Moechars et 
al., 1999)  
PDAPPSwInd 
(J20) 
Tg construct: hAPPSwInd 
Promoter: PDGFB 
Injected: C57BL/6 x 
DBA/2F2 embryos 
WM spatial memory 
retention, acquisition, 
deficits 6-7 months (Palop 
et al., 2003). 
Total Aβ and Aβ42 overexpression 
in neocortical and hippocampus. 
High levels of Aβ42 resulted in age-
dependent formation of Aβ plaques 
in mutant hAPP mice but not wild-
type hAPP mice 
No NFTs. (Mucke et 
al., 2000)  
TgCRND8 APPSwe/Ind 
(KM670/671NL+V717F)/ 
hamster prion promoter 
At 3 months impairment in 
acquisition and learning 
reversal in memory version 
of the Morris water maze. 
Immunization against Aβ42 
offset learning impairment. 
Aβ deposits at 3 months of age, by 
10 weeks levels of Aβ40 and Aβ42 
peptides 5-fold higher than 
endogenous mouse-APP. Dense-
cored plaques and neuritic pathology 
evident from 5 months of age. 
Activated microglia appears 
concurrently with plaques. 
No NFTs. Rapid 
progression does 
not mirror  typical 
AD time course. 
(Chishti et 
al., 2001)  
APP/PS-1 hAPP (KM670/671NL and 
V717I, Thy-1 promoter) 
hPS-1 (M146L, HMG 
promoter). 
Not reported. High levels of Aβ40 and Aβ42 before 
plaque deposition. Hippocampal 
pyramidal cell loss. Astrocytosis in 
the surrounding of the plaques. 
No NFTs. (Wirths et 
al., 2001) 
APPsw/Tau 
(P301)/PS1 
(M146V) 
 3x tg 
APPSw(KM670/671NL) 
Tau(P301L)/Thy-1.2 
promoter/ co-microinjected 
into pronuclei of embryos 
of PS1M14VKI mice 
Cognitive impairments by 4 
months as 
retention/retrieval deficits 
occur prior to any plaques 
or tangle pathology. Early 
cognitive deficits can be 
reversed by 
immunotherapy. 
Age related and progressive plaques 
and tangles. Deficits in LTP correlate 
with accumulation of intraneuronal 
Aβ. Tau and APP expression doubled 
in homozygous mice in hippocampus 
and cerebral cortex. Hippocampal 
neuronal loss. 
 (Oddo et al., 
2003b)  
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One year later, Hsiao et al. (Hsiao et al., 1996) generated the Tg2576 mouse. This mouse 
expresses the most abundant APP isoform, APP695 with the Swedish double mutation K670N/M671L, 
under the control of the hamster prion protein promoter (hPrP). These mice overexpress mutant APP 5-
fold over the endogenous mouse APP expression. First amyloid plaques are detected at 9 to 12 months 
in the frontal, temporal, entorhinal cortex, hippocampus, presubiculum, subiculum in a similar 
distribution as in PDAPP mice. Phosphorylated tau is detected in dystrophic neurites, but no tau 
filaments and no NFTs (Tomidokoro et al., 2001a; Tomidokoro et al., 2001b).  Although these mice do 
not show significant neuronal loss, Spires et al. (Spires et al., 2005) showed pronounced synaptic loss 
near senile plaques. This disruption appeared to extend beyond plaques. 9-10 months old Tg2576 mice 
develop memory deficits (Hsiao et al., 1996). These behavioural alterations correlate with the 
development of amyloid plaques and with impaired long-term potentiation (Hsiao et al., 1996).  
 
Another APP transgenic mouse model, the APP23 mouse, was developed by Sturchler-Pierrat 
and colleagues in 1997. In contrast to Tg2576 and PDAPP mice, APP23 mice express  the 751 amino 
acid isoform of hAPP (hAPP751) with the Swedish mutation (K670N, M671L)(sweAPP) driven by a 
neurons specific Thy 1 promoter. Transgene derived APP levels exceed the endogenous APP by 7-fold 
(Andra et al., 1996; Sturchler-Pierrat et al., 1997). Histopathologically, these mice are characterized by 
progressive Aβ-deposition. The first deposits appear at 5-6 months of age (Sturchler-Pierrat et al., 
1997; Thal et al., 2006a).  In addition to parenchymal Aβ accumulation, CAA leads to vessel wall 
degeneration, often associated with hemorrhage (Winkler et al., 2001). Less frequently CAA-
associated vasculitis and minor aneurysms were seen (Winkler et al., 2001). Activated microglia and 
astrocytes are associated with Aβ-plaques in these mice (Sturchler-Pierrat et al., 1997). Dystrophic 
neurites and tau protein hyperphosphorylation has also been described (Sturchler-Pierrat et al., 1997), 
although NFT are not found. APP23 mice show a selective neuronal death in the hippocampus section 
CA1 (Calhoun et al., 1998), which is not observed in Tg2576 and PDAPP mice. APP23 mice show an 
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age-dependent decline of spatial memory capacities. From 3 months of age, these mice displayed 
major learning and memory deficits. In addition to the cognitive deficits, APP23 mice also show 
disturbed activity patterns. At 6 months of age lower activity levels and different exploration 
behaviour are seen compared to control mice (Kelly et al., 2003; Van Dam et al., 2003).  
Since APP transgenic mice do not show the full spectrum of AD-like pathology, double and 
triple transgenic mice have been developed with the aim of obtaining a mouse model showing the full 
spectrum of AD pathology. Double transgenic mice expressing a double mutation in APP (Swedish 
APP mutation APPK670N, M671L and APPV717I under the mouse Thy-1 promoter) and mutant presenilin-1 
(PS-1 M146L under the pHMG promoter) showed for example a significant age-related loss of 
hippocampal pyramidal cells. NFTs were not seen in these mice. Since the PS-1 mutation itself may 
accelerate age-related degeneration, it is difficult to clarify the role of Aβ for neurodegeneration in this 
APP/PS-1 mouse model. 
 
In 2003, Oddo et al (2003b) reported a transgenic mouse model for AD that develops both 
plaques and NFT pathology in AD-related brain regions, a triple transgenic mouse (3xTg-AD) 
harbouring PS1M146V, APPSwe, and tauP301L trangenes (Table 2). Diffuse and fibrillar Aβ-aggregates are 
seen in this mouse model (Oddo et al., 2003b). Aβ-aggregates are initially seen in neocortical areas 
and also develop Aβ-deposits in limbic areas with the age. In contrast, tau aggregates occur first in the 
hippocampus and then expand into further cortical regions (Oddo et al., 2003a). Both Aβ-deposition 
and tau-aggregates follow a very similar expansion pattern as described in AD patient. In 3xTg-AD 
mice intracellular Aβ is the first manifestation of pathology and extracellular Aβ-deposits occur prior 
to the aggregates of abnormal tau protein (Oddo et al., 2003a). Synaptic dysfunction, including LTP 
deficits, occurs in an age related manner but prior to the onset of Aβ-pathology. Moreover, the 
occurrence of intraneuronal Aβ-immunoreactivity in CA1 pyramidal neurons correlates with 
impairments in synaptic plasticity including deficits in LTP. Therefore, 3xTg-AD mice reproduce the 
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neuropathology of AD best and became a very useful model for analyzing the relation between the 
different proteins involved in AD. However, the upregulation of three mutant proteins at a time does 
not allow the investigation of the pathological effects of one of these proteins alone.  
In so doing, the APP23 mouse is the only transgenic mouse model for AD that overexpresses a 
distinct protein, sweAPP, and exhibits selective neuronal death in a brain region that is affected in AD. 
Thus, this mouse model allows the investigation of Aβ-induced neurodegeneration in the absence of 
other contributing factors such as the expression of mutant PS1 or mutant Tau protein.  
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2. AIMS OF THE STUDY 
 
In order to clarify the neurodegenerative mechanisms involved in AD it is essential to identify 
the proteins or protein aggregates that induce nerve cell degeneration. The amyloid hypothesis 
indicates that Aβ has an essential pathogenetic role in AD (Hardy et al., 1989; Hardy, 1990). 
Therefore, it needs to be clarified whether Aβ is capable of altering different types of neurons in a 
model similarly as in AD. In the event that Aβ-toxicity is the driving force for AD-related pathology, 
one would expect Aβ to be capable of inducing degeneration of vulnerable neurons in a mouse model 
for AD. Although there is increasing evidence that soluble aggregated forms of Aβ are neurotoxic 
(Kayed et al., 2003; Kokubo et al., 2005b), it is not clear whether these forms of Aβ alter vulnerable 
neurons selectively and why distinct types of neurons are altered by Aβ whereas others are resistant.  
In the human brain Aβ-deposition shows a hierarchical sequence in which the different areas of 
the brain become step-by-step involved. It is necessary to examine whether this sequence represents 
the time course of AD-related Aβ-deposition or just different pathologies in different individuals. 
To address these questions this study was aimed at, 
1) examining that the step-by-step development of Aβ-deposition in the brain represents the time 
course of cerebral β-amyloidosis or just different pathologies in different individuals, 
2) clarifying which Aβ forms are capable of inducing neurodegeneration, 
3) identifying whether Aβ is capable of inducing selective degeneration of distinct types of 
neurons, 
4) correlating the effects of Aβ-induced neurodegeneration with the Aβ content, the Aβ plaque 
load, and the overall distribution of Aβ plaques in the mouse brain, and 
5)  comparing Aβ induced neurodegeneration in the mouse model with that in AD brain.
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3. MATERIAL AND METHODS 
 
3.1. Material 
 
3.1.1. Animals 
 
Heterozygous female APP23 and wild-type mice were provided by the Novartis Institutes for 
Biomedical Research (Basel, Switzerland) free of charge. 
Age (months) 3  5  11  15  26  
Wild-type n = 8 n = 13 n = 14 n = 9 n = 20 
APP23 n = 12 n = 16 n  = 13 n = 15 n = 16 
 
 
3.1.2. Consumables 
 
 All consumables used for this study were purchased from the following companies: LaboMedic 
(Bonn, Germany), VWR International (Darmstadt, Germany), and Schleicher & Schuell GmbH 
(Dassel, Germany). 
 
3.1.3. Chemicals 
 
All the chemicals used for this study were purchased from the following companies: 
Invitrogene (Karlsruhe, Germany), Merck (Darmstadt, Germany), Molekularbiologisches & 
biochemisches Labor (Bielefeld, Germany), Molecular Probes (Eugene, OR, USA), peqLab (Erlangen, 
Germany), Roche (Mannheim, Germany), Sigma (Taufkirchen, Germany).  
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3.1.4. Solutions 
 
For  genotyping: 
 DNA digestion buffer 
Components Concentration Company 
Tris HCl  50mM Sigma, Taufkirchen, Germany 
EDTA 100 mM  Sigma, Taufkirchen, Germany 
SDS 0,5 % Sigma, Taufkirchen, Germany 
 
 PCR reaction mixture 
Components Concentration Company 
dNTPs-mix 0.2mM peqLab, Erlangen, Germany 
MgCl2 1mM Invitrogene, Karlsruhe, Germany 
Forward primer 5pmol/µl Invitrogene, Karlsruhe, Germany 
Reverse primer 5pmol/µl Invitrogene, Karlsruhe, Germany 
Taq polymerase 1.25U/50µl Invitrogene, Karlsruhe, Germany 
ddH2O according to final 
concentration  
Delta Select GmbH, Pfullingen, 
Germany 
 
 50x TAE (Tris Acetate EDTA), pH 8.5 
Chemicals Amount Company 
TRIS Base 2M Sigma, Taufkirchen, Germany 
Glacial acetic acid 57% Sigma, Taufkirchen, Germany 
Na2EDTA 2H2O 0.1M Sigma, Taufkirchen, Germany 
ddH2O To 1 liter Millipore GmbH, Schwalbach, 
Germany 
 
 2% agarose gel 
Components Amount Company 
Agarose 2 % peqLab, Erlangen, Germany 
EtBr 0.6M Sigma, Taufkirchen, Germany 
TAE 1x 100 ml See 50x TAE 
 
For the DiI tracing method: 
 0.05M Tris Buffer Solution (TBS), pH 7.5 
Components Amount Company 
Trizma Base 0.05M Sigma, Taufkirchen, Germany 
NaCl 0.15M Sigma, Taufkirchen, Germany 
HCl 4.4% Sigma, Taufkirchen, Germany 
ddH2O To 1 liter Millipore GmbH, Schwalbach, 
Germany 
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 0,2M Phosphate buffer solution (PBS), pH 7.6 
Components Amount Company 
Na2HPO4 0.16M Sigma, Taufkirchen, Germany 
NaH2PO4 0.02M Sigma, Taufkirchen, Germany 
ddH2O To 1 liter Millipore GmbH, Schwalbach, 
Germany 
 
 2.6 % Phosphate buffer paraformaldehyde solution (PFA), pH 7.6 
Components Amount Company 
PFA 2.6 % Sigma, Taufkirchen, Germany 
PBS 0.2M, pH 7.6 500ml See PBS solution 
ddH2O 500ml Millipore GmbH, Schwalbach, 
Germany 
 
26g PFA in 500 ml dH2O solution, heat to 60ºC, neutralized with NaOH 1M, add 500ml of PBS 0.2M, adjust pH to 
7.6. 
 
 Perfusion solution 
Components Amount Company 
heparin 0.5% Roche, Mannheim, Germany 
in TBS 0.05M pH 7.4 To 1 liter See TBS solution 
 
 Tracing solution 
Components Concentration Company 
Iodocetic acid 0.8% Sigma, Taufkirchen, Germany 
Sodium periodate 0.8% Sigma, Taufkirchen, Germany 
DL-Lysine 0.1M Sigma, Taufkirchen, Germany 
in PFA solution To 1 liter See PFA solution 
 
For immunohistochemistry: 
 Reduction solution 
Components Concentration Company 
Methanol 10% Merck, Darmstadt, Germany 
H2O2 30% Sigma, Taufkirchen, Germany 
in TBS, pH 7.6 0.05M See TBS solution 
 
 Blocking solution 
Components Concentration Company 
DL-Lysine 0.1M Sigma, Taufkirchen, Germany 
Triton X 0.25% Sigma, Taufkirchen, Germany 
in BSA  10% Sigma, Taufkirchen, Germany 
 
3. Material and Methods 
                                    
 
25 
3.1.5. Primer sequence of APP and Actin 
 
Gene Forward primer Reverse primer Size 
(bp)  
Company 
APP 5’-GAATTCCGACATGACTCAGG-3’ 5’-GTTCTGCTGCATCTTGGACA-3’ 246 Invitrogene, Karlsruhe, 
Germany 
Actin 5’-GACAGGATGCAGAAGGAGAT-3’ 5’-TTGCTGATCCACATCTGCTG-3’ 146 Invitrogene, Karlsruhe, 
Germany 
 
 
3.1.6. Summary  table of used antibodies 
 
Antibody Antigen Species Dilution Pretreatment Reference Source 
Aβ1−42 Aβ1-42 Rabbit 1:750 Formic acid (Wild-Bode et al., 
1997) 
Gift of C. Haass 
MBC40 Aβ32-40 Monoclonal 1:20 Formic acid (Yamaguchi et al., 
1998) 
Gift of H. Yamaguchi 
MBC42 Aβ37-42 Monoclonal 1:200 Formic acid (Yamaguchi et al., 
1998) 
Gift of H. Yamaguchi 
22C11 N-Terminal 
of APP 
Monoclonal 1:75 no (Weidemann et al., 
1989) 
Chemicon 
GAP 43 GAP43 Rabbit 1:75 no (Masliah et al., 1992a) Chemicon 
 
 
3.1.7. Equipment 
 
Centrifuge Eppendorf 5417R (Eppendorf, Hamburg, Germany) 
Injectomat Injectomat 2000 (Fresenius Homo Care, Alzerau-Hörstein, 
Germany) 
Magnetic stirrer Magnetic stirrer (Heidolph Instruments, Solingen, Germany) 
Microscopes Fluorescence Microscope Leica DMLB (Leica, Bersheim, 
Germany) 
 Scanning Confocal Microscope Leica TSC NT (Leica, 
Bersheim, Germany) 
 Zeiss Stemi 200C Microscope (Carl Zeiss Lichtmikroskopie, 
Göttingen, Germany) 
Oven T6, Kendro Laboratory products (Langenselbold, Germany) 
pH-meter pH-meter 210 (Hanna Intruments, Kehl am Rhein, Germany) 
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Scale Scale (Kern & Sohn GmbH, Balingen-Frommern, Germany) 
Softwares Axiovision AC 4.2 image analysis software (Carl Zeiss 
Lichtmikroskopie, Göttingen, Germany) 
 CorelDRAW Graphics Suite 12 (CorelDRAW, 
Unterschleissheim, Germany 
 EndNote v8 (Thomson ISI ResearchSoft, Philadelphia, PA, 
USA) 
 Image ExpertTM Software (Bio-Rad Laboratories GmbH, 
Munich, Germany) 
 Image J, Imaging Processing and Analysis Software (NIH, 
Bethesda, MD, USA) 
 Leica FireCam Software(Leica, Bersheim, Germany) 
 Leica TCS Software (Leica, Bersheim, Germany) 
 LogXact 5.0 Software (Cytel Software Corporation, 
Cambridge, MA, USA) 
 Microsoft Office 2003, Microsoft Deutschland GmbH, 
Unterschleissheim, Germany)  
 SPSS software (Chicago, IL, USA) 
Thermocycler Thermocycler T1 (Biometra, Goettingen, Germany) 
Thermomixer Thermomixer Comfort (Eppendorf, Hamburg, Germany) 
Transilluminator BioRad Gel Doc1000 (Bio-Rad Laboratories GmbH, Munich, 
Germany) 
Vibrotome Leica VT1000S (Leica, Bersheim, Germany) 
Vortex Vortex-Genie 2 (Scientific Industries, Inc., NY, USA) 
 
 
3.2. Animal models 
 
APP23 mice were generated by The Novartis Institutes for Biomedical Research (Basel, 
Switzerland) as previously described (Sturchler-Pierrat et al., 1997) and continuously back-crossed to 
C57BL/6. An expression construct containing a murine Thy-1 promoter was used to drive neuron-
specific expression of human mutant APP751 with the Swedish double mutation 670/671 KM -> NL. 
Heterozygous female APP23 mice and female wild-type littermates were analyzed (see 3.1). All mice 
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were kindly provided by Novartis Institutes for Biomedical Research (Basel, Switzerland). Genotype 
information was provided. 
 
3.3. Confirmation of APP23 mice genotype 
 
To confirm the genotype of each mouse polymerase chain reaction (PCR) analysis of frozen tail 
samples was performed. Tail samples were taken immediately before starting perfusion fixation. A 
sample from each mouse was digested with 0.5% Proteinase K (Invitrogen, Karlsruhe, Germany) in 
DNA digestion buffer (see materials), overnight at 55ºC in a thermocycler (Biometra, Goettingen, 
Germany). On the next day samples were centrifuged (13000 rpm/ 10 min./ 4ºC) (Eppendorf, 
Hamburg, Germany). The supernatants were transferred to tubes containing 500µl of isopropanol 
(Merck, Darmstadt, Germany) and centrifuged (13000 rpm/ 10 min./ 4ºC). After removal of the 
supernatant 500µl of 70% ethanol (Merck, Darmstadt, Germany) was added, samples were vortexed 
and centrifuged (13000 rpm/ 10 min./ 4ºC). Supernatant was discarded. After the pellet was dried it 
was resuspended in 140 µl of Millipore water.  
PCR reaction mixture was prepared as indicated above (see materials) including APP primers. 
5µl of DNA per mouse was mixed with 20 µl of PCR reaction mixture. PCR was run with the 
optimized conditions mentioned below. Amplification of Actin gene was carried out as internal 
positive control.  
The optimized conditions for human APP gene PCR were: preheating at 94ºC, followed by 
94°C for 45 sec., 58°C for 45 sec., 72°C for 45 sec., during 35 cycles, followed by 72°C for 5 min., 
and stored at 4°C.  
The PCR reaction products were analyzed on ethidium bromide (EtBr) stained 2% agarose 
(peqLab, Erlangen, Germany) gels. The DNA samples were loaded into wells of the gel. pUC 19 MsP 
I was used as DNA-marker (Molekularbiologisches & biochemisches Labor, Bielefeld, Germany). 
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Electrophoresis was run with 1xTAE running buffer under voltage to 180V until the dye marker was 
migrated appropriately. After separation of the PCR products the EtBr-stained gels were transferred to 
the ultraviolet (UV) transilluminator (Bio-Rad Laboratories GmbH, Munich, Germany) to demonstrate 
visible reaction products and were photographed using digital camera system and Image ExpertTM 
Software (Bio-Rad Laboratories GmbH, Munich, Germany). 
 
3.4. Western blot analysis 
 
For the confirmation of APP overexpression in APP23 mice western blot data were kindly 
provided by The Novartis Institutes for Biomedical Research (Basel, Switzerland).  
 
 Forebrain hemispheres (excluding olfactory bulb, cerebellum and brainstem) were weighed 
and homogenized by sonication in 10 volumes of buffer (20 mM Tris-HCl pH 7.6, 137 mM sodium 
chloride, protease inhibitor cocktail (Complete, Roche Molecular Biochemicals, Mannheim, 
Germany)). For immunoprecipitation, homogenates were supplemented with 1% sodium dodecyl 
sulfate, heated to 95°C for 3 minutes, diluted with 9 volumes of homogenization buffer and cleared by 
centrifugation at 15°C for 15 minutes at 20000xg. Aβ-peptides were immunoprecipitated using the 
monoclonal antibody β1 reacting with the amino-terminus of Aβ (Schrader-Fischer and Paganetti, 
1996) and protein G coated magnetic beads (Dynal Biotech, Hamburg, Germany). Precipitates or 
whole homogenates were separated on 10% Tris-bicine gels with 8 M urea as described (Klafki et al., 
1996; Staufenbiel and Paganetti, 1999). In this system, Aβ1-40 migrates slower than Aβ1-42. Proteins 
were transferred to Immobilon-P membranes (Millipore, Carrigtwohill, Ireland). Aβ-peptides were 
fixed to the membrane by heating it to 95°C for 3 minutes in phosphate buffered saline (PBS) (Sigma, 
Taufkirchen, Germany) (Staufenbiel and Paganetti, 1999). Full length APP was detected with rabbit 
antiserum APP-C8 raised against the carboxy-terminal amino acids of APP (Schrader-Fischer and 
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Paganetti, 1996) which are identical in mice and humans. Transgene derived APP and Aβ were 
detected with the monoclonal antibody 6E10 (Signet, MA, USA). After incubation of the blots with the 
appropriate peroxidase coupled secondary antibodies (Jackson Immunoresearch, Soham, UK and 
Sigma, Taufkirchen, Germany), proteins were detected by visualizing chemiluminescence (ECL 
advance, Amersham Pharmacia Biotech, NJ, USA) on autoradiographic films (Hyperfilm ECL, 
Amersham Pharmacia Biotech, NJ, USA).  
 
3.5. Enzyme linked immunoabsorvent assay (ELISA) 
 
Quantification data of the Aβ levels were kindly provided by The Novartis Institutes for 
Biomedical Research (Basel, Switzerland). Statistical analysis was performed in the Department of 
Neuropathology, University Hospital of the Rheinische Friedrich-Wilhelms-University of Bonn, Bonn 
(Germany). 
For quantification of Aβ levels by ELISA, forebrain homogenates from APP23 mice of each 
age group (3 months: n=6; 5 months: n=6; 11months: n=4; 15 months: n=7) were supplemented with 
concentrated formic acid to a final concentration of 70%.  After 15 minutes of incubation on ice and 
mixing every 5 minutes, the samples were neutralized by addition of 19 volumes 1 M Tris base 
supplemented with protease inhibitor cocktail. The extracts were cleared by centrifugation (20000xg 
for 15 min at 4°C). Supernatants from young (3 or 5 months) APP23 mice were directly loaded on 
sandwich ELISA plates for quantification of Aβ peptides (Aβ1-40: ELISA from IBL, Hamburg, 
Germany; Aβ1-42: ELISA from Innogenetics, Ghent, Belgium). Supernatants from 11 and 15 months 
old APP23 mice were diluted as necessary in dilution buffers supplied with the ELISAs. Standard 
curves were prepared with synthetic peptides Aβ1-40 and Aβ1-42 purchased from Bachem (Bubendorf, 
Switzerland) and diluted in extracts of non-transgenic mouse forebrain prepared in parallel as 
described above. Each sample was analyzed in duplicate.  
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3.6. Labeling of commissural neurons 
 
To detect Aβ-induced neuronal alterations in APP23 mice we examined commissural neurons 
of the frontocentral cortex known to be vulnerable in AD (Alzheimer, 1907; Terry et al., 1981; Braak 
and Braak, 1991b; Duyckaerts and Dickson, 2003). The DiI-tracing method was used to study the 
morphological integrity of the commissural neurons. To confirm that the staining pattern seen with the 
DiI-tracer is not the result of methodological limitations of the DiI-method, a second tracing method in 
vivo tracing with biotinylated dextrane amine, was used. 
 
3.6.1. DiI tracing 
 
Commissural neurons of the frontocentral cortex were labeled using DiI (1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindolcarbocyanine perchlorate) as a tracer. DiI is a highly fluorescent lipophilic 
carbocyanine that becomes incorporated into the cell membrane of those cells that are in contact with 
the dye (Haugland, 2005). Other cells are not labeled. It is used for anterograde and retrograde tracing 
of neuronal cells in vivo (Honig and Hume, 1986, 1989; Wouterlood, 1993) and in fixed tissues 
(Godement et al., 1987; Baker and Reese, 1993; Wouterlood, 1993). Once applied, the dye diffuses 
laterally within the plasma membrane of the cells in contact with the dye, resulting in a staining of the 
entire cell (Haugland, 2005). This dye allows precise Golgi-like tracing of neurons in postmortem 
fixed tissue in a quality similar to in vivo tracing methods using rhodamine tracers even in only weakly 
traced neurons (Galuske and Singer, 1996). 
For DiI-tracing brains of 3, 5, 11, and 15 months old APP23 (3 months: n=6; 5 months: n=9; 11 
months: n=8; 15 months: n=8) and wild-type mice (3 months: n=6; 5 months: n=12; 11 months: n=13; 
15 months: n=9) were studied. Animals were treated in agreement with the German law on the use of 
laboratory animals. Mice were anesthetized. Perfusion was performed transcardially with Tris buffered 
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saline (TBS) supplemented with heparin (pH 7.4) followed by the injection of 0.1 M PBS (pH 7.4) 
containing 2.6% paraformaldehyde (PFA), 0.8% iodoacetic acid, 0.8% sodiumperiodate, and 0.1 M D-
L Lysine. The brains were removed in total and postfixed in 2.6% phosphate buffered PFA (pH 7.4) 
containing 0.8% iodoacetic acid, 0.8% sodiumperiodate, and 0.1 M D-L Lysine (Galuske et al., 2000). 
Three days later a single crystal (approximately 0.3 mm3) of the carbocyanine dye DiI (Molecular 
Probes, Eugene, OR, USA), was implanted into the left frontocentral cortex, 1 mm rostrally from the 
central sulcus, 2 mm laterally from the middle line and 1 mm deep in the cortex (Fig.6). After 
incubation in 2.6% phosphate buffered PFA for at least 3 months at 37°C, 100 µm thick coronal 
vibratome sections were cut. Sections were mounted in TBS for microscopic analysis.  
 
 
 
Figure 6: Application site of the DiI tracer in the mouse 
brain. The DiI tracer was implanted into the left 
frontocentral cortex: 1 mm rostrally from the central 
sulcus, 2 mm laterally from the median sagital plane, and 1 
mm deep in the cortex (arrow). In so doing, the tracer was 
placed into layers I-V of the frontocentral cortex. 
 
3.6.2. In vivo tracing with biotinylated dextrane amine 
 
The technical part of this tracing method was kindly performed by Christine Stadelmann and 
Angelika Escher at the Department of Neuropathology, Georg-August University, Göttingen 
(Germany). Microscopic analysis and documentation was performed at the Department of 
Neuropathology, University Hospital of the Rheinische Friedrich-Wilhelms-University of Bonn, Bonn 
(Germany). 
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As a second tracing method to confirm the data with the DiI tracing method, we used a 
biotinylated dextrane amine (BDA; Molecular Probes; probes.invitrogen.com) tracer for in vivo 
tracing. BDA is characterized by its high molecular weight, good water solubility, low toxicity, and 
relative inertness. The α-1,6-polyglucose linkages are resistant to cleavage by most endogenous 
cellular glycosidases. Thus, BDA is ideally suitable as a long-term tracer for living cells. It stains 
neuronal processes anterogradely as well as retrogradely (Haugland, 2005).  
14-week-old C57Bl/6 mice were anaesthetized with ketamin/rompun and placed in a 
stereotactic frame. After incision of the skin, a fine hole was drilled into the skull 0.1mm caudal and 
0.2mm lateral to bregma. A finely drawn glass capillary was stereotactically placed into the frontal 
cortex (approximal depth 0.5mm), and 1µl BDA was slowly injected over a 3 minute period. After 
withdrawal of the capillary, the skin wound was closed by suture, and animals were allowed to survive 
for 3 days. For tissue sampling, animals were anaesthetized, perfused transcardially with 4% PFA, and 
dissected. Brain slices were embedded in gloop, a mixture of egg albumin, gelatine, sucrose and 
gluaraldehyde, and 50µm vibratome sections were cut. BDA was visualized using an avidin-
peroxidase based method (vectastain; www.vectorlabs.com) with diaminobenzidine as chromogen. 
Sections were dehydrated, and coverslipped.  
 
3.7. Microscopic and quantitative analysis of commissural neurons 
 
In layer III of the frontocentral cortex of the right hemisphere, contralateral to the implantation 
site of the tracer, the morphology of traced commissural neurons was examined. The traced neurons 
were assigned to different types according to their morphology. Then the number of traced 
commissural neurons of each type in wild-type mice was compared with that in APP23 mice. For 
qualitative and quantitative analysis 10 consecutive sections (100 µm thickness each) representing a 
tissue block of 1 mm thickness were studied for each mouse. Analysis started at the anterior 
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commissure setting the caudal limit of the investigated tissue block. For each coronal section, the 
medial boundary of the region investigated was set as the vertical line at the cingulum that separated 
the cingulate cortex (Cg) from secondary motor cortex (M2) (Fig. 7). The horizontal boundary was set 
as the horizontal line separating the primary somatosensory cortex (S1) from the insular cortex (I) (Fig. 
7). 
CC
Cg
S1
I
Pirac
Tracer
Application
M2
M1
 
Figure 7: The schematic representation shows a coronal section of the 
mouse brain at the level of the tracer application site. Layer III 
commissural neurons within the contralateral frontocentral cortex 
labeled by the DiI tracer were studied in the secondary and primary 
motor cortex (M1 and M2) and the somatosensory cortex (S1) (area 
marked in red) as determined by the following coordinates: the medial 
boundary was established as the vertical (red) line that separates the 
cingulate cortex (Cg) from the secondary motor cortex (M2). The 
horizontal limit was referred to as the horizontal (blue) line that 
separated the primary somatosensory cortex (S1) from the insular 
cortex (I). 
 
For the qualitative analysis a laser scanning confocal microscope (Leica TCS NT, Leica, 
Bensheim, Germany) was used. Stacks of two dimension (2D) images were superimposed digitally 
using the Image J Imaging Processing and Analysis software (NIH, Bethesda, MD, USA), and three 
dimension (3D) data sets were generated for the visualization of neurons with their entire dendritic 
tree.  
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For quantification of the commissural neurons in APP transgenic and wild-type mice, traced 
neurons in layer III were counted in the region of interest depicted in Fig. 1 in 10 consecutive sections 
of the tissue block taken for qualitative and quantitative analysis using a fluorescence microscope 
(Leica DMLB, Leica, Bensheim, Germany). In so doing, we analyzed a cortex volume of 5-6 mm3 in 
each mouse. Mean and median values of the number of traced neurons were calculated and compared 
between wild-type and APP23 mice. Statistical analysis was performed using the Mann-Whitney U-
Test to compare wild-type and APP23 mice. Poisson regression was used to identify differences in the 
number of traced neurons among the different phases of Aβ-deposition in the brain. Appropriate 
corrections for multiple testing were made. 
 
3.8. Immunohistochemistry 
 
3.8.1. Aβ-plaques detection and quantification 
 
Immunohistochemistry was performed for the detection and quantification of Aβ-plaques. Free 
floating sections were incubated with reduction solution (see material) for 30 min. Sections were 
pretreated for 5 min in formic acid, washed and incubated in blocking solution (see materials) for 90 
min. After blocking, sections were incubated with an anti-Aβ antibody (polyclonal rabbit (Wild-Bode 
et al., 1997), 1/750, 24h at 22°C). The polyclonal antibody detected Aβ1-40 as well as Aβ1-42. To 
separately detect Aβ40 and Aβ42 positive material, additional sections were stained with monoclonal 
antibodies specifically detecting the C-terminus of Aβ40 (MBC40 (Yamaguchi et al., 1998), 1/20, 24h 
at 22°C, formic acid pretreatment) and Aβ42 (MBC42 (Yamaguchi et al., 1998), 1/200, 24h at 22°C, 
formic acid pretreatment). The primary antibody was detected with a biotinylated secondary antibody 
and the Avidin-Biotin-Peroxidase (ABC) complex (Biomeda, CA, U.S.A), and the reaction was 
visualized with 3,3-diaminobenzidine (DAB) 3.2mM (Sigma) (Hsu et al., 1981). Sections were washed 
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in PBS and dH2O. On glass slides the sections were dried for 30 minutes at 37ºC. Dried sections were 
put in Xylene for 5 minutes and mounted in Corbit Balsam (Hecht, Hamburg, Germany).  
Quantification of the Aβ-plaque load was performed in an area of the frontocentral neocortex in 
one selected section with plaques using a Zeiss Stemi2000C microscope and Axiovision AC 4.2 image 
analysis software (Carl Zeiss Lichtmikroskopie, Göttingen, Germany). The Aβ-plaque load was 
measured for plaques stained with the polyclonal antibody raised against Aβ1-42 (Wild-Bode et al., 
1997) according to the following determination: 
Aβ-plaque load = area of plaques detected with anti-Aβ1-42 antibodies in a given region of interest x 100
area of the region of interest  . 
Mean values of the Aβ-plaque load were compared between 3, 5, 11, and 15 months old APP23 mice 
with ANOVA. 
 
3.8.2. Staging of Aβ-deposition in APP23 mice 
 
To characterize the expansion of Aβ-deposition in the mouse brain we determined the phases of 
Aβ-deposition valid for human and APP-transgenic mouse brain (Thal et al., 2002a; Wiederhold et al., 
2004; Thal et al., 2006a)(Tab. 3).  
          Table 3. Phases of Aβ-deposition in APP23 mice brain. 
Phase 0 Absence of Aβ deposits 
Phase 1 Aβ deposits in the neocortex 
Phase 2 Aβ deposits in the neocortex and allocortex 
Phase 3 Aβ deposits in the neocortex, allocortex and basal ganglia 
Phase 4 Aβ deposits in the neocortex, allocortex, basal ganglia, thalamus and upper brainstem 
Phase 5 Aβ deposits in the neocortex, allocortex, basal ganglia, thalamus, upper and lower 
brainstem and cerebellum 
 
 Paraffin embedded tissue from 26 months of age wild type and APP23 mice was additionally 
included in this study for the characterization of Aβ-deposition in old animals.  4 µm paraffin sections 
were de-waxed in xylene (5 min, two times), and hydrated through serial alcohols (100%, 2 min., two 
times; 95%, 2 min.; 90%, 70%, 2 min.; 50%, 2 min.; 30%, 2 min.) to TBS. The same 
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immunohistochemistry procedure as mentioned above was followed (see 3.8.1). After Aβ-deposits 
were seen in positive controls, the sections were dehydrated through serial alcohols (30%, 2 min.; 
50%, 2 min.; 70%, 2 min.; 90%, 2 min, 95%, 2 min, 100%, 2 min, two times), propanol (2 min), 
xylene (5 min., two times), and finally mounted with Corbit Balsam (Hecht, Hamburg, Germany). 
 
3.8.3. Analysis of axonal sprouting and axonal damage 
 
Growth association protein 43 (GAP43) is a marker for differentiating neurons and is expressed 
in elevated levels of developing or regenerating neurites indicating axonal growth (Knyihar-Csillik et 
al., 1992) as well as of dystrophic neurites in neuritic plaques (Masliah et al., 1992a). APP is also 
involved in neuritic growth, and it is co-expressed within GAP43 positive in aberrant sprouting 
neurites (Masliah et al., 1992a). Antibodies against GAP43 and APP were used for studying axonal 
sprouting. To examine axonal sprouting following axonal or neuronal damage, sections of the area of 
interest of each mouse were stained with antibodies directed against APP (22C11 (against N-terminal 
of APP), monoclonal mouse, Chemicon, 1/75, 24h at 22°C) and against GAP43 (polyclonal rabbit, 
Chemicon, 1/75, 24h at 22°C). Immunohistochemistry was performed as reported in 3.8.1. without 
formic acid pretreatment.  
 
3.9. Statistical analysis 
 
Statistical analysis was performed using the SPSS 11.0 program (SPSS, Chicago, IL, USA) and 
LogXact 5.0 software (Cytel Software Corporation, Cambridge, MA, USA). In case of multiple testing 
p-values were corrected adequately.  
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4. RESULTS 
 
4.1.  Subpopulations of commissural neurons in layer III of the frontocentral cortex 
 
Using retrograde tracing with DiI, three different types of commissural neurons were identified 
in layer III of the frontocentral cortex in wild-type and APP23 mice at the age of 3-, 5-, 11- and 15-
month (Fig. 8A-F). The first type of commissural neurons referred to as type I, showed a DiI-labeled 
perikaryon of pyramidal shape, an apical dendrite, and multiple basal dendrites with a heavily ramified 
and spiny dendritic tree. Ramification of the dendrites was characterized by branching of apical and 
basal dendrites into primary branches exhibiting secondary and tertiary ramifications within layer III 
(Fig. 8A, D). The basal dendrites were restricted to layers II/III. The apical dendrite showed further 
ramification within the molecular layer. These type I commissural neurons were predominantly located 
in the upper part of layer III (Fig. 8D). 
The second type of commissural neurons, referred to as type II, exhibited a DiI-labeled 
perikaryon of pyramidal shape. The apical and basal dendrites were detectable but further ramification 
and dendritic spines were less frequently observed and the basal dendrites were thicker than those of 
type I commissural neurons (Fig. 8B, E, F). 3D-reconstruction revealed that the basal dendrites of type 
II commissural neurons start branching distant from the perikaryon (Fig. 8F). Commissural neurons of 
type II showed dendritic ramification and spines in the molecular layer as detected by following the 
apical dendrite in consecutive sections and, thus, represent the classical pyramidal cell morphology. 
These neurons were most frequently located in the lower part of layer III. Branches of their basal 
dendrites were also seen in the upper part of layer IV (Fig. 8E, F).  
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Figure 8: Three types of commissural neurons traced in the frontocentral cortex of wild-type mice. A, B, 
and C show the typical pattern of these three types of neurons as characterized in 100 µm thick sections 
after tracing with DiI. Type I commissural neurons are characterized as pyramidal shaped neurons with 
apical (white arrow) and basal (unfilled arrow) dendrites creating a heavily ramified and spiny dendritic 
tree showing secondary and tertiary branches within layer III. The axon leaves the perikaryon at the base 
(unfilled arrow head) (A). These neurons are mainly located within the upper part of layer III (D). The 
second type of commissural neurons is the sparsely ramified pyramidal neuron. These neurons are also 
characterized by a pyramidal cell body and traced apical (white arrow) and basal (unfilled arrow) 
dendrites. These cells represent the classical pyramidal cells in layer III. There is almost no further 
ramification of the apical and basal dendrite detectable in this type of neurons within layer III. The basal 
dendrites start branching distant from the perikaryon as shown in a 3D-reconstruction of serial scans (F). 
The axon is visible at the base of the perikaryon (unfilled arrow head) (B). These neurons are 
preferentially found in the lower part of layer III (E, F). C: Non-pyramidal commissural neurons referred 
to as type III commissural neurons, are characterized by a circular cell body. A few dendrites arise from 
the perikaryon (arrow head).  There is no further ramification seen in this type of neurons. The axon is 
not seen in this section. Type III commissural neurons do not exhibit a distinct predilection site within 
layer III (F, I). G-I: Tracing with BDA confirms the staining pattern of the three types of commissural 
neurons as seen with DiI-tracing. A-C show DiI-traced neurons in wild-type mice at 11 months of age, 
D-F in those of 5 months of age. A-C and F represent 3D-stacks of 16 images of cells in 1,25-1,75 µm 
distance recorded with the laser scan confocal microscope; D and E are images digitally captured with 
the Leica DMLB-microscope. G-I: Commissural neurons traced with biotinylated dextrane 3 days before 
death in wild-type mice of 14 weeks of age mice. Calibration bar in C valid for A: 55 µm, B, C: 40 µm. 
Calibration bar in F valid for D, E: 35 µm, F: 50 µm. Calibration bar in I valid for G-I: 35 µm. 
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The third type of commissural neurons, referred to as type III, did not exhibit clearly 
distinguishable apical and basal dendrites within layer III. Only the cell body with a circular shape was 
clearly labeled with the tracer. Single, very thin dendrites without spines were labeled in layer III (Fig. 
8C, F). These neurons did not show a predilection site in layer III. They occurred in the upper as well 
as in the lower parts of this cell layer.  
In all types of commissural neurons the axon left the neuron at the base and was part of the 
callosal commissural fiber system. In vivo tracing of wild-type mice with BDA confirmed the staining 
pattern and the existence of three different types of commissural neurons seen in the DiI-traced 
sections (Fig. 8G-I). 
 
4.2.  Morphological alterations of commissural neurons in APP23 mice 
 
At 3 months of age there were no differences between wild-type and APP23 mice in the 
morphology of the commissural neurons (Fig. 9A, B). In contrast, type I commissural neurons were 
morphologically altered in APP23 mice compared to wild-type mice at 5, 11, and 15 months of age 
(Fig. 9C, D).  In APP23 mice, the apical dendrite was shorter than in wild-type animals (Fig. 9C, D). 
The basal dendrites exhibited a non-symmetric pattern, short secondary or tertiary branches and their 
diameter was often reduced (Fig. 9D). In comparison, in wild-type mice this type of neurons showed a 
symmetrical architecture of the basal dendrites and secondary and tertiary branches were longer than in 
APP23 transgenic mice (Fig 9C, D). Altered type I commissural neurons in APP23 mice were often 
located distant from Aβ-plaques identified by subsequent immunostaining with anti-Aβ1-42 or by Aβ-
plaque-induced autofluorescence (Thal et al., 2002b). 
There were no apparent differences in the morphological patterns of type II and type III 
commissural neurons among APP23 and wild-type mice. 
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Figure 9: DiI-traced type I commissural neurons in the frontocentral cortex of 3- and 11-
month-old wild-type and APP23 mice. A: Type I commissural neurons in layer III of the 
frontocentral cortex show a highly ramified dendritic tree in 3-month-old wild-type mice. 
The basal dendrites exhibit secondary and tertiary branches and are symmetrically 
organized. B: In APP23 mice of 3 months of age there are no significant differences in 
the architecture of the dendritic tree when compared to that of wild-type animals. C: In 
11 months old wild-type animals the dendritic tree of a type I commissural neuron shows 
further ramifications. The dendritic tree has still a perfect symmetric architecture. D: 
Type I commissural neuron in a 11-month-old APP23 mouse exhibits a dendritic tree that 
shows a non symmetric architecture of the basal dendrites. A number of basal dendrites 
are small and shrunken (arrow) while others still appear in regular size (unfilled arrow 
head). This pattern of type I neurons is strikingly different from that at 3 months of age 
and that of wild-type animals at 11 months of age. Calibration bar: 22 µm.     
 
4.3.  Selective reduction of type I commissural neurons in APP23 mice 
 
Quantitative analysis of traced commissural neurons in 5-15 months of age wild-type mice 
showed that type II commissural neurons were predominant (60-80%), while type I (10-20%) and type 
III neurons (10-20%) were less abundant. The number of traced type I neurons appeared to decrease 
with age but this trend failed significance (trend test: p=0.108) (Fig. 10). In 3-month-old animals a 
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similar percentage of type I neurons was found (10-20%) while type II neurons were less predominant 
(40-45%). In these animals the number of type III neurons was higher than in older animals (p<0.01; 
Analysis of variance (ANOVA) corrected for multiple testing by using the Tamhane T2 post hoc-test) 
and covered 40-45% of all traced commissural neurons (Fig. 10). 
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Figure 10. Diagram representing the mean number and standard 
deviation type I, type II and type III commissural neurons in wild-
type mice at 3, 5, 11, and 15 months of age. At 3 months of age, the 
number of type III neurons/mm3 was higher than in older animals. In 
5-15 months of age wild-type animals, type I and type III 
commissural neurons were less frequently detectable than type II 
commissural neurons and represented each 10-20% of the 
commissural neurons. ** p<0.01. 
 
The overall number of commissural neurons did not show significant differences between wild-
type and transgenic mice at a given age (Mann-Whitney U-test, corrected for multiple testing: 3 
months: p=0.9917; 5 months: p=0.2126; 11 months: p=0.9579; 15 months: p=0.3232). However, with 
increasing expansion of Aβ-deposition throughout the brain the total number of neurons decreased 
(Poisson regression analysis controlled for age: risk-ratio = 0.967, 95% confidence interval = 0.941 – 
0.9938, p<0.05; trend-test: p<0.05).  
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Figure 11: Diagram representing the mean number and standard 
deviation of type I commissural neurons in wild-type and APP23 
mice at 3, 5, 11, and 15 months of age. APP23 mice show a 
decrease of more than 90% of the type I commissural neurons 
compared to wild-type mice at 5, 11, and 15 months of age.* 
p<0.05; ** p<0.01. 
 
In detail, the number of traced type I commissural neurons in APP23 mice was reduced by 
more than 90% compared to that of wild-type mice at 5, 11 and 15 months of age (Mann-Whitney U-
Test, corrected for multiple testing: 5 months APP23 vs. wild-type: p<0.05; 11 months APP23 vs. 
wild-type: p<0.005; 15 months APP23 vs. wild-type: p< 0.01) but not at 3 months of age (Mann-
Whitney U-Test, corrected for multiple testing: 3 months APP23 vs. wild-type: p=0.9917) (Fig. 11). 
With the expansion of Aβ-deposition the number of traced type I neurons decreased significantly 
(Poisson regression analysis controlled for age: risk-ratio = 0.3417, confidence interval = 0.174 – 
0.6712, p<0.005). 
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Figure 12: Diagram representing the mean number and standard 
deviation of type II commissural neurons in each strain at 3, 5, 11, 
and 15 months of age. There are no significant differences in the 
number of type II commissural neurons at 3, 5, and 11 months of 
age between wild-type and APP23 mice. Only in 15-month-old 
APP23 mice the number of type II commissural neurons is 
decreased compared to wild-type animals. At this age, less type II 
neurons are labeled when compared with younger APP23 mice 
(Kruskal-Wallis H-test: p<0.005, trend-test: p<0.05). * p<0.05; ** 
p<0.01. 
 
 
The number of type II commissural neurons did not show significant differences between wild-
type and APP23 mice at 3, 5 and 11 months of age (Mann-Whitney U-Test, corrected for multiple 
testing: 3 months p=1; 5 months p=0.182; 11 months: p=0.9375) (Fig. 12). However, at 15 months of 
age a significant reduction of traced type II neurons was observed in APP23 mice compared to wild-
type animals (Mann-Whitney U-Test, p-values corrected for multiple testing: 15 months: p< 0.05). 
Over all ages, the number of traced type II neurons decreased significantly with the expansion of Aβ-
deposition (Poisson regression analysis controlled for age: risk-ratio = 0.9432, confidence interval = 
0.9033 – 0.9849, p<0.01). 
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Figure 13: Diagram representing the mean number and standard 
deviation of type III commissural neurons in each strain at 3, 5, 11, 
and 15 months of age. Neither at 3 nor at 5, 11, and 15 months of 
age, there is significant differences in the number of nonpyramidal 
commissural neurons between wild-type and APP23 mice. Between 
3 months of age and 5 - 15 months of age there is a reduction of 
~80% of type III neurons.* p<0.05; ** p<0.01. 
 
The number of type III commissural neurons did not significantly differ among APP23 and 
wild-type mice neither at 3 nor at 5, 11, or 15 months of age (Mann-Whitney U-Test, corrected for 
multiple testing: APP23 vs. wild-type: 3 months: p=0,8651; 5 months: p=0.9749; 11 months: p=0.453; 
15 months: p=0.3232) (Fig. 13). In addition, there was no significant change in the number of traced 
type III neurons throughout the phases of Aβ-deposition (Poisson regression analysis controlled for 
age: risk-ratio = 1.0409, p=0.1533). 
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4.4.  Aβ production in APP23 mice  
 
Western blot analysis confirmed overexpression of human APP and production of Aβ1-40 and 
Aβ1-42 in APP23 mice (Fig. 14). Full length APP (flAPP) was detected both in wild-type as well as in 
APP23 mice. hAPP was detected in APP23 mice at 5 and 11 months of age with the same intensity. 
However, the levels of Aβ1-40 and Αβ1-42 clearly increased from 5 to 11 months of age.   
 
 
Figure 14: Western blot analysis of APP and Aβ in forebrain homogenates of 
wild-type and APP23 mice at the ages of 5 and 11 months. Full length APP 
(flAPP) is detected with an antibody directed against mouse and hAPP (APP-C8). 
Transgenic hAPP is stained with a human specific Aβ antibody which also reacts 
with human APP (6E10). In the lowest panel, Aβ1-40 and Aβ1-42 are detected with 
the 6E10 antibody after immunoprecipitation with the anti-Aβ antibody β1 except 
for the 11-month-old APP23 sample. To compensate for the Aβ accumulation, this 
sample was diluted and represents 80 times less forebrain tissue than the other 
samples. Both Aβ1-40 and Aβ1-42 are detectable in APP23 mice at 5 and 11 months 
of age while no significant amounts of Aβ are seen in wild-type mice.  
 
Quantification of total Aβ levels by ELISA in APP23 mice at 3, 5, 11, and 15 months of age 
showed a significant exponential increase of Aβ with the age (Tab. 3) (ANOVA corrected for multiple 
testing by using the Tamhane T2 post hoc-test: Aβ1-40 p<0.001; Aβ1-42 p<0.001). Total Aβ1-40 levels, 
thereby, were higher than total Aβ1-42 levels (sign test: p<0.001). Between 3 and 5 months of age total 
Aβ levels did not differ significantly (ANOVA corrected for multiple testing by using the Tamhane T2 
post hoc-test: Aβ1-40 p=0.786; Aβ1-42 p=0.963). However, between 5 and 11 months of age an increase 
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of both, Aβ1-40 and Aβ1-42 was seen (ANOVA corrected for multiple testing by using the Tamhane T2 
post hoc-test: Aβ1-40 p<0.05; Aβ1-42 p<0.01), as well as between 11 and 15 months of age (ANOVA 
corrected for multiple testing by using the Tamhane T2 post hoc-test: Aβ1-40 p<0.01; Aβ1-42 p<0.001). 
 
 
Table 3: Mean levels of Aβ1-40 and Aβ1-42 concentration in the forebrain of APP23 mice at 3, 5, 11 and 15 months of age 
determined by ELISA. 
 
 
 
 
4.5.  Aβ-plaque load in the frontocentral cortex of APP23 mice 
 
Immunohistochemistry with a polyclonal antibody detecting Aβ1-40 as well as Aβ1-42, revealed 
no Aβ-deposits in wild-type mice at 3-, 5-, 11-, or 15-month. APP23 mice did not show plaques at 3 
months of age (Fig. 15,17A). Single plaques in the frontocentral neocortex were observed in 67% of 
the APP23 mice at 5 months of age (ANOVA corrected for multiple testing by using the Tamhane T2 
post hoc-test: p<0.05). However, differences in the Aβ-plaque load did not reach significance between 
3- and 5-month-old APP23 mice (ANOVA corrected for multiple testing by using the Tamhane T2 
post hoc-test: p=0.096) (Fig. 15). Between 5- and 11-month-old APP23 mice the Aβ-plaque load in the 
frontocentral cortex increased (Fig. 15) (ANOVA corrected for multiple testing by using the Tamhane 
T2 post hoc-test: p<0.005). At 11 months of age all APP23 mice showed Aβ-plaques in the 
frontocentral cortex. Between the ages of 11 and 15 months there was a further increase in the Aβ-
plaque load within the frontocentral cortex (ANOVA corrected for multiple testing by using the 
Tamhane T2 post hoc-test: p<0.001).  
    Age 
(months) 
Aβ1−40 
(pmol/g) 
SD  Aβ1−42 
(pmol/g) 
SD 
 
3 22,51 +/- 3,16  2,25 +/- 0,36  
5 25,94 +/- 5,60          p<0.05 2,46 +/- 0,40         p<0.01 
11 5447,09 +/- 1437,67           1668,36 +/-256,46       
15 28919,74 +/- 7699,72           p<0.01 6019,74 +/-1146,88      p<0.001 
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Figure 15: Quantification of the Aβ-plaque load in the 
frontocentral cortex of APP23 mice. There is no significant 
difference in the Aβ-plaque load between 3- and 5-month-old 
animals. The single plaques seen in 5-month-old animals did not 
lead to a significant increase in the Aβ-plaques load (p=0.096). 
Between 5 and 11 as well as between 11 and 15 months the Aβ-
plaque load increases. Boxes represent mean values. Bars indicate 
the standard deviation. * p<0.05; ** p<0.01; ***p<0.001. 
 
 
 
 
4.6. Expansion of Aβ-deposition in APP23 mice 
 
Immunohistochemistry with polyclonal antibody detecting Aβ1-40 as well as Aβ1-42 showed the 
first Aβ-deposits in APP23 mice at 5 months of age (Fig. 16B). Single plaques in the frontocentral 
cortex were observed in 67% of the APP23 mice representing the phase 1 of Aβ-deposition as it was 
mention before (see 4.5) (Tab. 4) (ANOVA corrected for multiple testing by using the Tamhane T2 
post hoc-test: p<0.05).  No other brain area showed Aβ-plaques at this age. 11-month-old mice often 
exhibited an additional involvement of allocortical brain regions, i.e. the hippocampal formation and 
the cingulate gyrus in Aβ-deposition (Fig. 16C) representing phase 2 of Aβ-deposition (Fig. 17, Tab.  
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Figure 16. Aβ-deposition in APP-transgenic mice expands into additional brain regions 
with increasing age. A: 3-month-old APP23 mice do not show Aβ-deposits. B: Aβ-
deposition begins in female APP23 mice at 5 months of age in the neocortex (boxed area). 
Here, the first amyloid plaques can be identified (inset). C: At 11 months of age, 
allocortical areas, such as the hippocampus, exhibit Aβ-plaques (arrow) in addition to 
neocortical areas. However, the basal ganglia as well as the thalamus do not show plaques 
at this stage. D: Fifteen-month old female APP23 mice form Aβ plaques in the basal 
ganglia (striatum; arrows, boxed area). E: Aβ deposits in the brain stem occur in mice at 25 
months of age (arrows, boxed area). The inset indicates the diffuse nature of these plaques. 
Calibration bar: A-D: 730 µm, insets B, D, E: 25 µm. 
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4) (ANOVA corrected for multiple testing by using the Tamhane T2 post hoc-test: p<0.005). Between 
11 and 15 months of age an additional Aβ-plaques occurred in the basal ganglia as well as in the 
thalamus (Fig. 16D) indicating phase 3 of Aβ-deposition (ANOVA corrected for multiple testing by 
using the Tamhane T2 post hoc-test: p<0.001) (Fig. 17, Tab. 4).  
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Figure 17: Distribution of Aβ-plaques as described by the 
phases of Aβ-deposition (Thal et al., 2002a) in APP23 mice. 
3-month-old animals do not show plaques. Aβ-deposition 
starts with the first plaques in 5-month-old APP23 mice. 
67% of these mice exhibited Aβ-plaques in a distribution 
pattern related to phase 1. A significant expansion of Aβ-
deposition as represented by an increasing phase is seen 
with advancing age. Boxes represent mean values. Bars 
indicate the standard deviation. * p<0.05; ** p<0.01; 
***p<0.001. 
 
To confirm that Aβ-deposition in APP23 mice follows the same hierarchical involvement of 
different regions as in human brain (Thal et al., 2002a), additional paraffin sections from 25-month-old 
APP23 mice were included for the staging study. At 25 months of age, 75% of the APP23 mice 
showed additional Aβ-deposits in the midbrain representing phase 4 of Aβ-deposition (Fig. 16E) and 
18,2% of the mice showed an involvement of the pons representing phase 5 of Aβ-deposition (Fig. 17, 
Tab. 4) (ANOVA corrected for multiple testing by using the Tamhane T2 post hoc-test: p<0.001). Aβ-
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deposits in APP23 mice exhibited equal staining patterns with anti-Aβ42 and anti-Aβ40 antibodies at all 
ages. 
 
           
           Table 4. Percentage of mice exhibiting Aβ-deposits in a given phase at a given age. 
 
 
 
 
 
 
4.7. Axonal sprouting of commissural neurons in APP23 mice 
 
Immunohistochemistry with antibodies directed against APP and GAP43 showed the presence 
of immunolabeled, thickened axon endings in the frontocentral cortex of 3-month-old wild-type and 
APP23 mice indicative for axonal sprouting (Fig. 18A-D). In the DiI-traced sections we found 
collateral sprouting in wild-type and APP23 mice at 3 months of age. Single axons of commissural 
neurons with growth cones were seen in layers II and III of the frontocentral cortex of the DiI-traced 
sections (Fig. 18E). In 5-month-old mice thickened axon endings of commissural neurons in DiI-traced 
sections were no longer observed. However, single APP and GAP43-positive, thickened axon endings 
were found in APP23 mice but not in wild-type mice at this age (Fig. 18F-I).  
Sprouting of commissural neurons around plaques was observed in 11- and 15-month-old 
APP23 mice in DiI-traced sections (Fig. 19C) as well as in APP and GAP43-stained sections (Fig. 
19A, B). Wild-type mice did not show sprouting of commissural neurons in this age in DiI-traced 
sections. Only single APP and GAP43-positive sprouting axons were detected in the frontocentral 
cortex of 15-month-old wild-type mice. 
 
Age (months) Phase 0 Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 
3 100,0% 0,0% 0,0% 0,0% 0,0% 0,0% 
5 33,3% 66,7% 0,0% 0,0% 0,0% 0,0% 
11 0,0% 33,3% 66,7% 0,0% 0,0% 0,0% 
15 0,0% 0,0% 11,1% 88,9% 0,0% 0,0% 
26 0,0% 0,0% 0,0% 6,3% 75,0% 18,2% 
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Figure 18: Sprouting and degenerating axons in the frontocentral cortex of wild-type (wt) and APP23 
mice. A-E: APP and GAP43-positive thickened axonal endings in the frontocentral neocortex of wild-type 
and APP23 mice at 3 months of age. APP positive axonal endings (arrow in B) are found in layer III of the 
frontocentral cortex (A, B representing the enlargement of the boxed area in A). The axonal endings occur 
in wild-type as well as in APP23 mice and appear as thickened growth cones of sprouting axons (arrows in 
B, C) also exhibiting GAP43 (arrow in D). DiI-tracing also shows swollen axon endings (arrows) in layer 
III of the contralateral hemisphere indicating an involvement of commissural neurons in these changes (E). 
F-I: At 5 months of age wild-type mice do not show APP or GAP43 positive sprouting or degenerating 
axons (F). In contrast, APP23 mice exhibit single APP positive, thickened axonal endings (arrows in H-I; 
H represents the enlargement of the boxed area in G). Calibration bar: A, F, G: 300 µm, B-E, H, I: 20 µm. 
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Figure 19. At 11 and 15 months of age APP positive dystrophic neurites are seen 
in association with plaques (arrows in B representing the enlargement of the boxed 
area in A). Some of these neurites were identified as aberrant sprouting axons 
(arrows) arising from commissural neurons by DiI-tracing around amyloid plaques 
in the contralateral frontocentral cortex (C). The amyloid nature of the plaque is 
demonstrated by the exhibition of the Aβ-plaque specific blue autofluorescence 
under UV-light excitation (Thal et al., 2002b). Calibration bar: A: 300 µm. B: 40 
µm, C: 70 µm. 
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5. DISCUSSION 
 
In this study, it is shown that three types of commissural neurons in layer III of the mouse 
frontocentral cortex can be identified using tracing methods. These different neuron types are 
hierarchically affected by Aβ-induced neurodegeneration. The deposition of the first Aβ-plaques is, 
thereby, associated with the onset of neurodegeneration in APP23 mice. Expansion of Aβ-deposition 
into further brain regions goes along with increasing age and the involvement of a second type of 
commissural neurons in neurodegeneration and confirms that the step-by-step expansion of Aβ-
deposits in the brain represents the time course of Aβ-deposition. The complexity of the dendritic 
morphology is, thereby, related to the vulnerability of these different types of neurons. 
 
5.1.  Types of commissural neurons in the frontocentral cortex of the mouse brain 
 
This study confirms and extends previous reports that describe different types of pyramidal and 
non-pyramidal neurons projecting through the corpus callosum (Hughes and Peters, 1992; Martinez-
Garcia et al., 1994). The distinction of the three types of commissural neurons in the mouse 
frontocentral cortex is based on their morphological appearance after retrograde tracing with DiI. It is 
confirmed by using biotinylated dextrane in vivo tracing as an additional method. 
Type I commissural neurons are characterized by a pyramidally shaped perikaryon and apical 
and basal dendrites with a heavily ramified and spiny dendritic tree within layer II-III. Type II 
commissural neurons represent neurons with a pyramidally shaped perikaryon and apical and basal 
dendrites, which do not show extensive further ramifications in layer III in a given tissue section. 
However, 3D-reconstruction revealed that the basal dendrites of these neurons start branching distant 
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from the perikaryon. Type III commissural neurons are non-pyramidal neurons and have a circular cell 
body with a few tiny dendrites. 
In contrast to the other types of commissural neurons, type III neurons are reduced in number 
in 5-, 11- and 15-month-old animals in comparison to 3-month-old mice regardless of the genotype. 
Thus, an effect of Aβ or APP-overexpression is not responsible for the reduction of type III neurons 
because wild-type mice show the same effects as APP23 mice. To explain this finding further studies 
are required. Developmental or maturation-related phenomena (Fritzsch et al., 1997) might be 
involved.  
All three types of neurons were found in all mice studied and their axons projected through the 
corpus callosum to the contralateral hemisphere. Since tracer-labeled type I, type II, and type III 
commissural neurons were visible in the same section close to one another and type II neurons showed 
dendritic ramification in the molecular layer it seems unlikely that DiI tracing of neurons without a 
ramified dendritic tree is due to dysfunctional tracing rather than to the exhibition of specific 
morphological types of neurons. Galuske and Singer (Galuske and Singer, 1996) also reported that 
once a given neuron is stained with DiI all cell processes will be labeled. Moreover, a second tracing 
method based on in vivo transport of the biotinylated dextrane (Reiner et al., 2000) confirmed the 
presence of three different types of commissural neurons. 
The heterogeneous morphological pattern of commissural neurons in the frontocentral cortex of 
mice confirms and extends the finding of other authors that the visual cortex contains different types of 
callosal commissural neurons (Voigt et al., 1988; Buhl and Singer, 1989; Martinez-Garcia et al., 1994). 
They also reported the presence of commissural neurons of pyramidal and non-pyramidal types. 
Cortical commissural neurons project to different layers of the contralateral hemisphere (Wise and 
Jones, 1976; Martinez-Garcia et al., 1994). Therefore, the different types of frontocentral commissural 
neurons may terminate in different layers of the contralateral hemisphere and may have specific 
functions in commissural information processing. 
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5.2. Degeneration of commissural neurons in APP23 mice 
 
Two of the three types of commissural neurons were reduced in number when traced in APP23 
transgenic mice. Type I commissural neurons were significantly reduced in number in APP23 mice 
beginning at 5 months of age. The surviving type I commissural neurons in these mice exhibited 
alterations of the dendritic tree in comparison to wild-type animals. The other types of commissural 
neurons did not show obvious differences between transgenic and wild-type mouse lines at this point 
in time. The second type of neurons showing degenerative changes, type II commissural neurons, was 
reduced in number at 15 months of age. With increasing age, Aβ-plaque load, and Aβ-expansion the 
second type of neurons became involved in Aβ-induced neurodegeneration. However, type III 
commissural neurons were not altered. 
The degeneration of type I and type II commissural neurons in APP23 mice can be interpreted 
1) as a result of selective neuronal death, 2) as the result of dendritic alterations, or 3) as a consequence 
of axonal damage (Fig. 20). The first possibility of selective neuronal death is supported by the 
decrease of the total number of neurons in the hippocampus of APP transgenic mice indicating that 
neuronal loss can result from abnormal production of Aβ (Fig. 20B) (Calhoun et al., 1998; Schmitz et 
al., 2004). A second supporting argument is that in Down syndrome patients overexpressing APP 
(Neve et al., 1988) neuronal loss is accentuated in layer III of the frontocentral cortex (Davidoff, 
1928). On the other hand, the second possibility that the reduction of the heavily ramified type of 
commissural neurons is due to dendritic changes is supported by a recent finding indicating that 
dendritic length is reduced in a specific group of dentate granule cells in PDAPP transgenic mice (Fig. 
20C) (Wu et al., 2004). Together with our finding of an asymmetrically ramified dendritic tree in 
altered type I commissural neurons it is likely that dendritic alterations would at least precede neuronal 
death. In so doing, it is possible that degenerated type I and type II neurons may appear 
morphologically as type II or type III commissural neurons, respectively. The third hypothesis for the 
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reduction of the number of traced commissural neurons is a loss of axonal connectivity between the 
hemispheres (Fig. 20D). This hypothesis is supported by axonal sprouting seen in aged APP-transgenic 
mice (Phinney et al., 1999; Teter and Ashford, 2002) indicating regeneration after axonal injury 
(Deller and Jucker, 2001) and by the degeneration of myelinated axons (Bartzokis et al., 2003), 
especially in the corpus callosum of human AD-cases (Weis et al., 1991; Yamauchi et al., 1993; 
Hampel et al., 1998). However, our tracing study as well as that of Phinney et al. (Phinney et al., 1999) 
did not exhibit collateral sprouting of commissural neurons in 5-month-old APP23 mice already 
exhibiting a decrease in the number of traced type I commissural neurons. Abnormal axonal sprouting 
of commissural neurons in APP23 mice starts at 11 months of age and, therefore, axonal damage may 
not be the first step in the degeneration of these neurons. 
 
Figure 20. Possible interpretations for the reduction of traced commissural neurons represented in a coronal section of 
mouse brain at the frontocentral level. The schematic representation shows commissural neurons (red) with axonal 
terminals in contact with the area where the tracer was applied. Blue circles are located in the areas potentially involved in 
the degeneration of these commissural neurons. Figure A shows no neuronal damage. B: One explanation for the reduced 
number of traced neurons the death of these neurons. C: Dendritic alterations may also explain the degeneration of these 
neurons. D: Loss of connectivity due to axonal damage, may lead to a reduction of traced commissural neurons although 
the cell soma of the neurons is still alive. In this event one would expect collateral sprouting.  
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Single APP and GAP-43 positive neurites occur in the frontocentral cortex of APP23 mice at 5-
month indicative for axonal sprouting (Masliah et al., 1992a; Masliah et al., 1992b). Since 
commissural neurons do not show sprouting at this age, these APP and GAP-43 positive neurites 
represent sprouting axon terminals from non-commissural neurons. Such a sprouting is not seen in 
wild-type littermates. Aβ aggregates alone do not explain this selective sprouting. If Aβ aggregates 
alone would induce such a sprouting one would expect a contribution of neurites from all types of 
afferent neurons including commissural neurons. Therefore, it is tempting to speculate that these 
sprouting neurites in 5-months-old APP23 mice represent reactive sprouting following the 
degeneration of type I commissural neurons. 
Taken together, dendritic and axonal degeneration as well as neuronal death may be involved in 
the degeneration of type I and type II commissural neurons in a distinct sequence. In a first step 
dendritic processes of the nerve cells may degenerate presumably followed by axonal damage and, 
finally, nerve cell death. This sequence is similar to that seen in human AD for neurons accumulating 
NFTs (Bancher et al., 1989; Braak et al., 1994; Thal et al., 2000a). Here, neurodegeneration starts with 
dendritic and perikaryal accumulation of abnormal τ-protein, followed by the creation of NFTs, axonal 
accumulation of abnormal τ-protein in the target region of affected neurons and finally, neuronal death 
(Braak et al., 1994; Sassin et al., 2000; Thal et al., 2000a). 
 
5.3.   Aβ-deposition in APP23 mice 
 
In AD brain, different brain regions become involved in a distinct hierarchical sequence in β-
amyloidosis and NFT generation (Braak and Braak, 1991; Thal et al., 2002a). The evolution of Aβ-
deposition in APP23 mice follows the same sequence as in the human brain (Wiederhold et al., 2004; 
Thal et al., 2006a). The first phase shows only neocortical deposits. Additional involvement of 
allocortical regions characterized phase 2. In the third phase additional Aβ deposits were found in the 
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basal ganglia and the diecephalon whereas the midbrain and the lower brain stem nuclei become 
involved in phase 4. In the 5th and final phase Aβ-deposition also occurred in the pons and the 
cerebellum. In APP23 mice Aβ-deposition started with phase 1 at 5 months of age and then expanded 
with advancing age until 25 months of age. 
In so doing, the phases of Aβ-deposition in mice represent the time course of β-amyloidosis. 
The similar sequence of Aβ-deposition in the human brains suggests that this sequence represents the 
time course of AD-related pathology in the human brain. 
 
5.4. The relation between neurodegeneration and Aβ-pathology 
 
The loss of traceable type I commissural neurons in 5-month-old APP23 mice is associated 
with the deposition of the first Aβ-plaques within the frontal cortex of these animals. However, total 
Aβ-levels as well as the Aβ-plaque load did not differ significantly between 3 and 5 months old 
APP23 mice and there was no close spatial relationship between Aβ-plaques and degenerating 
commissural neurons in 5-month-old APP23 mice. This result indicates that Aβ-induced degeneration 
of neurons in the brain is not due to a simple increase in Aβ-levels or to Aβ-plaques themselves but 
due to qualitative changes in the status of Aβ-aggregation. Insofar, our results support other studies 
that the aggregation of Aβ to soluble Aβ-oligomers and/or fibrils is required for Aβ-toxicity (Podlisny 
et al., 1995; Kayed et al., 2003; Kim et al., 2003; Cleary et al., 2005) and go beyond the findings of 
other authors that Aβ-plaques induce local dendritic or neuritic degeneration (Tsai et al., 2004; 
Brendza et al., 2005; Spires et al., 2005). 
The finding of a hierarchical involvement of different types of neurons in Aβ-induced 
neurodegeneration further extents the present knowledge of Aβ-toxicity and argues in favor of a 
selective vulnerability of neurons to Aβ. Since this study is done in commissural neurons projecting 
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into the same area of the contralateral cortex, all neurons have the same axon lengths and all neurons 
function as commissural neurons. Axon lengths and the function of the neuron do, therefore, not 
appear to be responsible for the selective vulnerability of distinct types of neurons. All pyramidal 
neurons use excitatory amino acids (glutamate or aspartate) as transmitter (Conti et al., 1988; Giuffrida 
and Rustioni, 1989). Thus, at least type I and type II commissural neurons share a similar 
neurotransmitter but differ in their vulnerability. Therefore, the selective vulnerability of commissural 
neurons is most likely not due to the neurotransmitter of the different types of commissural neurons 
examined in this study. 
The most significant difference between type I, type II, and type III commissural neurons is the 
morphology of the dendritic tree (Fig. 21). Type I neurons exhibit a highly ramified dendritic tree with 
basal dendrites branching exclusively in layer III whereas type II neurons have a less ramified 
dendritic tree with dendrites also branching into layer IV. The type III neurons, in contrast, show only 
single dendrites without significant further ramification into secondary and tertiary dendrites. Thus, it 
is tempting to speculate that neurons with a highly ramified dendritic tree present a better target for 
toxic changes by oligomeric and/or fibrillar Aβ than neurons with a less ramified dendritic tree. This 
hypothesis is supported 1) by the finding of Roselli et al. (Roselli et al., 2005) that soluble Aβ-
oligomers induce NMDA-dependent degradation of postsynaptic density-95 protein at glutamatergic 
synapses on dendrites, 2) by the Aβ-induced inhibition of long-term potentiation (Wang et al., 2002), 
and 3) by the loss of dendritic spines seen in the vicinity of amyloid plaques (Tsai et al., 2004; Spires 
et al., 2005). Our finding that Aβ-induced neurotoxicity induces dendritic alterations of type I 
commissural neurons also argues in favor of the dendritic tree to be the primary target of Aβ-toxicity. 
The primary deposition of Aβ in the neocortical layers III and V (Braak and Braak, 1991b; Price et al., 
1991; Arriagada et al., 1992; Thal et al., 2000b) may support this hypothesis insofar as neurons with a 
dendritic tree branching exclusively within layer III and the molecular layer are target of Aβ-induced 
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neurodegeneration at an earlier point in time compared to neurons with basal dendrites escaping layer 
III by branching into layer IV. 
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Figure 21: Neurodegeneration in APP23 mice begins when Aβ aggregates can be detected as plaques for 
the first time at 5 months of age. Degeneration of neurons is represented in the figure by changing the 
color of the neurons to gray. The Aβ-level in the brain is not responsible for neurodegeneration at 5 
months of age because 3- and 5-month-old APP23 mice have similar Aβ-levels but only mice at 5 
months of age show neurodegeneration. There is selective vulnerability for Aβ-induced 
neurodegeneration of distinct types of commissural neurons. The type I commissural neurons (red) are 
most vulnerable to Aβ whereas type III neurons (orange) are not vulnerable and type II neurons (green) 
are significantly less vulnerable than type I neurons. The selective vulnerability against Aβ is related to 
the anatomy of the dendritic tree. Those neurons with the most ramified dendritic tree (type I 
commissural neurons marked in red) degenerate first. Those neurons with an almost negligible dendritic 
tree (type III commissural neurons marked in orange) do not degenerate while neurons with a moderately 
ramified dendritic tree (type II commissural neurons marked in green) degenerate when high levels of Aβ 
are present in the brain. 
 
 
These results in concert with that of other authors (Wang et al., 2002; Roselli et al., 2005) 
support the hypothesis that oligomeric and/or fibrillar Aβ-aggregates interact with dendrites and that 
neurons may degenerate when their dendrites are exposed to Aβ-aggregates. The size of the target for 
Aβ, i.e. the dendritic tree surface in a given area, presumably contributes to the vulnerability of 
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neurons to Aβ. The primary involvement of dendrites in Aβ-toxicity has also been demonstrated in 
dentate gyrus neurons (Wu et al., 2004). The interaction of ADDLs with the dendrites (Lacor et al., 
2004) could explain why Wu et al. (Wu et al., 2004) did not detect any Aβ-deposits although they 
found dendritic degeneration and it could also explain why 33 % of the 5 months old APP23 mice in 
our study did show neurodegeneration in the absence of Aβ-deposits. Moreover, it is highly unlikely 
that the principle function of a neuron (e.g., the function as a commissural neuron), the lengths of its 
axon, and the neurotransmitter used are the only factors determining selective vulnerability against Aβ. 
Our results show that theories of selective vulnerability in AD based upon the principal function and 
axon length of neurons (Braak et al., 2000) need to be supplemented by other factors to explain Aβ-
induced selective vulnerability. The morphology of the dendritic arbor presumably contributes to this 
selective vulnerability of neurons against Aβ as demonstrated here. 
 
5.5. The impact of Aβ-induced progressive neurodegeneration for AD 
 
Aβ alters different types of neurons in a distinct hierarchical sequence in an animal model for 
Aβ-pathology. After the onset of the degeneration of a distinct type of neurons a further type of 
neurons became involved with increasing Aβ-pathology. Other studies showing degeneration of 
different types of neurons in animal models for AD used double or triple transgenic mice (Lewis et al., 
2001; Oddo et al., 2003b; Schmitz et al., 2004). In these animals neurodegeneration cannot be 
addressed exclusively to Aβ because presenilin 1 (Oddo et al., 2003b; Schmitz et al., 2004) and/ or 
mutant τ-protein (Lewis et al., 2001; Oddo et al., 2003b) are co-expressed. In contrast, single APP-
transgenic mice used in this study allow the conclusion that Aβ alone is capable of inducing 
progressive neurodegeneration. Since humans show a hierarchical sequence in which different types of 
neurons develop AD-related neurofibrillary tangles and neuronal loss (Braak and Braak, 1991b) which 
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parallels the step-by-step expansion of Aβ-deposits into further brain regions (Thal et al., 2002a) 
similar to neurodegeneration and Aβ-deposition in mice these results suggest that Aβ is capable of 
inducing progressive neurodegeneration in AD. Therefore, these results support Aβ to be a major 
therapeutic target for AD treatment preferentially in pre-clinical stages to prevent progression of Aβ-
induced neurodegeneration. However, since Aβ supports progression of neurodegeneration Aβ-
lowering treatment strategies may also be helpful in later stages to stop the disease progression. 
 
5.6. Future perspectives 
 
The association between the expansion of Aβ pathology with cognitive decline in AD patients 
suggests that therapies aimed at lowering the production of Aβ might be beneficial. Passive as well as 
active immunization of APP-transgenic mice with anti-Aβ antibodies reduces the Aβ-load in the brain 
and improves the performance in cognition tests for mice (Schenk et al., 1999; Janus et al., 2000; 
Morgan et al., 2000). However, the first human patient died after Aβ-immunotherapy still showed 
severe neuronal pathology although the Aβ-load was lower than in untreated AD cases (Nicoll et al., 
2003). Therefore, the question arises whether the reduction of Aβ-deposits enables protection from 
neurodegeneration and/or allows recovery of degenerated neurons. Type I commissural neurons in 
APP23-transgenic mice are an ideal target to address this question. In the event that immunization after 
the onset of neurodegeneration in APP23 mice leads to a recovery of type I commissural neurons, it 
would indicate that Aβ-induced neurodegeneration is reversible as long as the neurons do not die. On 
the other hand, if Aβ-induced nerve cell damage is not reversible but immunization can be prevented 
when applied prior to the onset of degeneration, Aβ-lowering treatment strategies could stop the 
disease progression. Thus, the impact of Aβ-immunotherapy on vulnerable neurons such as the Type I 
commissural neurons will allow the determination of the most favorable therapeutic management for 
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Aβ-lowering therapies in the animal model and, in so doing, help to optimize its future clinical 
application in AD treatment.  
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6. CONCLUSIONS 
 
1) The expansion of Aβ-deposition into further brain regions as reported in the human brain 
represents the time course of the development of β-amyloidosis in the brain as seen in the mouse 
model. 
 
2) Aggregated forms of Aβ induce degeneration of commissural pyramidal neurons in the 
frontocentral cortex as soon as plaque deposition starts. 
 
3) Aβ-protein induces selective neurodegeneration in a distinct hierarchical sequence.  
 
 4) The involvement of additional neuronal subpopulation is associated with the increase of Aβ 
levels and with the expansion of Aβ-deposition into further brain regions. 
 
 5) Therefore, these results strongly support the hypothesis that Aβ itself is capable of inducing 
progressive neurodegeneration in AD as demonstrated in APP transgenic mice. 
 
 
 
 
 
 
 
7. References 
                                    
 
65 
 
7. REFERENCES 
 
 
Alzheimer A (1907) Ueber eine eigenartige Erkrankung der Hirnrinde. Allg Zschr Psych 64:146-148. 
Andra K, Abramowski D, Duke M, Probst A, Wiederhold KH, Burki K, Goedert M, Sommer B, 
Staufenbiel M (1996) Expression of APP in transgenic mice: a comparison of neuron-specific 
promoters. Neurobiol Aging 17:183-190. 
Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and 
neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral 
cortex of patients with Alzheimer's disease. Cereb Cortex 1:103-116. 
Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in 
nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 
42:1681-1688. 
Baker GE, Reese BE (1993) Using confocal laser scanning microscopy to investigate the organization 
and development of neuronal projections labeled with DiI. Methods Cell Biol 38:325-344. 
Ball MJ (1977) Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the 
hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl) 37:111-
118. 
Bancher C, Braak H, Fischer P, Jellinger KA (1993) Neuropathological staging of Alzheimer lesions 
and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 162:179-
182. 
Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Seitelberger F, Grundke-Iqbal I, Iqbal K, 
Wisniewski HM (1989) Tau and ubiquitin immunoreactivity at different stages of formation of 
Alzheimer neurofibrillary tangles. Prog Clin Biol Res 317:837-848. 
7. References 
                                    
 
66 
Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J (2003) White matter 
structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic 
resonance imaging study. Arch Neurol 60:393-398. 
Bertram L, Tanzi R (2003) Genetics of Alzheimer's disease. In: Neurodegeneration: The molecular 
pathology of dementia (Dickson D, ed), pp 40-46. Basel: ISN Neuropath Press. 
Blocq P, Marinesco G (1892) Sur les lesions et la pathologenie de l'epilepsie dite essentielle. Semaine 
Med 12:445-446. 
Braak E, Braak H, Mandelkow EM (1994) A sequence of cytoskeleton changes related to the 
formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87:554-567. 
Braak H, Braak E (1991a) Demonstration of amyloid deposits and neurofibrillary changes in whole 
brain sections. Brain Pathol 1:213-216. 
Braak H, Braak E (1991b) Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol 82:239-259. 
Braak H, Del Tredici K, Schultz C, Braak E (2000) Vulnerability of select neuronal types to 
Alzheimer's disease. Ann N Y Acad Sci 924:53-61. 
Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul 
SM, Hyman BT, Holtzman DM (2005) Anti-Abeta antibody treatment promotes the rapid 
recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 
115:428-433. 
Buhl EH, Singer W (1989) The callosal projection in cat visual cortex as revealed by a combination of 
retrograde tracing and intracellular injection. Exp Brain Res 75:470-476. 
Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel 
M, Sommer B, Jucker M (1998) Neuron loss in APP transgenic mice. Nature 395:755-756. 
7. References 
                                    
 
67 
Callahan CM, Hall KS, Hui SL, Musick BS, Unverzagt FW, Hendrie HC (1996) Relationship of age, 
education, and occupation with dementia among a community-based sample of African 
Americans. Arch Neurol 53:134-140. 
Cao X, Sudhof TC (2001) A transcriptionally [correction of transcriptively] active complex of APP 
with Fe65 and histone acetyltransferase Tip60. Science 293:115-120. 
Catala I, Ferrer I, Galofre E, Fabregues I (1988) Decreased numbers of dendritic spines on cortical 
pyramidal neurons in dementia. A quantitative Golgi study on biopsy samples. Hum Neurobiol 
6:255-259. 
Chan SL, Culmsee C, Haughey N, Klapper W, Mattson MP (2002) Presenilin-1 mutations sensitize 
neurons to DNA damage-induced death by a mechanism involving perturbed calcium 
homeostasis and activation of calpains and caspase-12. Neurobiol Dis 11:2-19. 
Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, 
Freedman SB, Morris RG (2000) A learning deficit related to age and beta-amyloid plaques in 
a mouse model of Alzheimer's disease. Nature 408:975-979. 
Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, 
French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, 
Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D (2001) Early-onset 
amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form 
of amyloid precursor protein 695. J Biol Chem 276:21562-21570. 
Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and 
serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55:1449-1455. 
Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) 
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat 
Neurosci 8:79-84. 
7. References 
                                    
 
68 
Cobb JL, Wolf PA, Au R, White R, D'Agostino RB (1995) The effect of education on the incidence of 
dementia and Alzheimer's disease in the Framingham Study. Neurology 45:1707-1712. 
Conti F, Fabri M, Manzoni T (1988) Glutamate-positive corticocortical neurons in the somatic sensory 
areas I and II of cats. J Neurosci 8:2948-2960. 
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines 
JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of 
Alzheimer's disease in late onset families. Science 261:921-923. 
Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B (2001) The amyloid precursor protein 
(APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes 
partially in a nuclear fraction of neurones in culture. J Neurochem 78:1168-1178. 
Davidoff LM (1928) The brain in mongolian idiocy: report of 10 cases. Archives of neurology and 
psychiatry 20:1229-1257. 
de Ruiter JP, Uylings HB (1987) Morphometric and dendritic analysis of fascia dentata granule cells in 
human aging and senile dementia. Brain Res 402:217-229. 
DeKosky ST, Scheff SW, Styren SD (1996) Structural correlates of cognition in dementia: 
quantification and assessment of synapse change. Neurodegeneration 5:417-421. 
Delaere P, Duyckaerts C, Masters C, Beyreuther K, Piette F, Hauw JJ (1990) Large amounts of 
neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically 
assessed, non-demented person. Neurosci Lett 116:87-93. 
Deller T, Jucker M (2001) Axonsrossung im Zentralnervensystem nach einer Läsion. Neuroforum:11-
20. 
Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56:321-339. 
Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A (1999) Behavioral disturbances in 
transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 
113:982-990. 
7. References 
                                    
 
69 
Duyckaerts C, Dickson DW (2003) Neuropathology of Alzheimer's disease. In: Neurodegeneration: 
The molecular pathology of dementia and movement disorders (Dickson D, ed), pp 47-65. 
Basel: ISN Neuropath Press. 
Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire HG, Kang J, Muller-Hill B, Masters CL, 
Beyreuther K (1988) Identification, transmembrane orientation and biogenesis of the amyloid 
A4 precursor of Alzheimer's disease. Embo J 7:949-957. 
Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by 
endothelin-converting enzyme. J Biol Chem 276:24540-24548. 
Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR (1993) Untreated blood pressure level is 
inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 138:353-
364. 
Esiri MM, Hyman BT, Beyreuther K, Masters CL (1997) Ageing and Dementia. In: Greenfields 
Neuropathology 6th Edition, 6. Edition (Graham DI, Lantos PL, eds), pp 153-233. London: 
Arnold. 
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, 
Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence 
of dementia: a Delphi consensus study. Lancet 366:2112-2117. 
Friedland RP (1993) Epidemiology, education, and the ecology of Alzheimer's disease. Neurology 
43:246-249. 
Fritzsch B, Farinas I, Reichardt LF (1997) Lack of neurotrophin 3 causes losses of both classes of 
spiral ganglion neurons in the cochlea in a region-specific fashion. J Neurosci 17:6213-6225. 
Galuske RA, Singer W (1996) The origin and topography of long-range intrinsic projections in cat 
visual cortex: a developmental study. Cereb Cortex 6:417-430. 
Galuske RA, Schlote W, Bratzke H, Singer W (2000) Interhemispheric asymmetries of the modular 
structure in human temporal cortex. Science 289:1946-1949. 
7. References 
                                    
 
70 
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, 
Donaldson T, Gillespie F, et al. (1995) Alzheimer-type neuropathology in transgenic mice 
overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527. 
Giuffrida R, Rustioni A (1989) Glutamate and aspartate immunoreactivity in cortico-cortical neurons 
of the sensorimotor cortex of rats. Exp Brain Res 74:41-46. 
Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and 
characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 
120:885-890. 
Godement P, Vanselow J, Thanos S, Bonhoeffer F (1987) A study in developing visual systems with a 
new method of staining neurones and their processes in fixed tissue. Development 101:697-
713. 
Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, Ball MJ (1994) Chemical 
characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of 
Alzheimer disease. J Biol Chem 269:10987-10990. 
Griffin WS, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 expression in different plaque 
types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 
54:276-281. 
Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Araoz C (1989) 
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and 
Alzheimer disease. Proc Natl Acad Sci U S A 86:7611-7615. 
Grober E, Kawas C (1997) Learning and retention in preclinical and early Alzheimer's disease. 
Psychol Aging 12:183-188. 
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal 
phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal 
pathology. Proc Natl Acad Sci U S A 83:4913-4917. 
7. References 
                                    
 
71 
Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, 
Koo EH, Schenk D, Teplow DB, et al. (1992) Amyloid beta-peptide is produced by cultured 
cells during normal metabolism. Nature 359:322-325. 
Hampel H, Teipel SJ, Alexander GE, Horwitz B, Teichberg D, Schapiro MB, Rapoport SI (1998) 
Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal 
degeneration in Alzheimer disease: a magnetic resonance imaging analysis. Arch Neurol 
55:193-198. 
Hardy J (1990) Molecular genetics of Alzheimer's disease. Acta Neurol Scand Suppl 129:29-31. 
Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20:154-159. 
Hardy JA, Goate AM, Owen MJ, Mullan MJ, Rossor MN, Pearson RC (1989) Modelling the 
occurrence and pathology of Alzheimer's disease. Neurobiol Aging 10:429-431; discussion 
446-428. 
Hashimoto T, Wakabayashi T, Watanabe A, Kowa H, Hosoda R, Nakamura A, Kanazawa I, Arai T, 
Takio K, Mann DM, Iwatsubo T (2002) CLAC: a novel Alzheimer amyloid plaque component 
derived from a transmembrane precursor, CLAC-P/collagen type XXV. Embo J 21:1524-1534. 
Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP (2002) Disruption of 
neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in 
models of Alzheimer's disease. J Neurochem 83:1509-1524. 
Haugland R (2005) The Handbook: A Guide to Fluorescence Probes and Labeling Technologies. 
U.S.A: Molecular Probes, Invitrogen detection technologies. 
Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski 
D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews 
PM, Jucker M (2004) Abeta is targeted to the vasculature in a mouse model of hereditary 
cerebral hemorrhage with amyloidosis. Nat Neurosci 7:954-960. 
7. References 
                                    
 
72 
Heston LL, Mastri AR, Anderson VE, White J (1981) Dementia of the Alzheimer type. Clinical 
genetics, natural history, and associated conditions. Arch Gen Psychiatry 38:1085-1090. 
Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van 
Broeckhoven C, Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of 
dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349:151-154. 
Honig MG, Hume RI (1986) Fluorescent carbocyanine dyes allow living neurons of identified origin 
to be studied in long-term cultures. J Cell Biol 103:171-187. 
Honig MG, Hume RI (1989) Dil and diO: versatile fluorescent dyes for neuronal labelling and 
pathway tracing. Trends Neurosci 12:333-335, 340-331. 
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) 
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 
274:99-102. 
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in 
immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) 
procedures. J Histochem Cytochem 29:577-580. 
Hughes CM, Peters A (1992) Types of callosally projecting nonpyramidal neurons in rat visual cortex 
identified by lysosomal HRP retrograde labeling. Anat Embryol (Berl) 186:183-193. 
Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997) Abeta 
deposition is associated with neuropil changes, but not with overt neuronal loss in the human 
amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059. 
Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee 
HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1-42-
degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and 
pathological deposition. Nat Med 6:143-150. 
7. References 
                                    
 
73 
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 
42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an 
initially deposited species is A beta 42(43). Neuron 13:45-53. 
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, 
French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, 
Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques 
in a model of Alzheimer's disease. Nature 408:979-982. 
Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM (1999) Total homocysteine 
and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. 
Am J Epidemiol 150:283-289. 
Kalus P, Braak H, Braak E, Bohl J (1989) The presubicular region in Alzheimer's disease: topography 
of amyloid deposits and neurofibrillary changes. Brain Res 494:198-203. 
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther 
K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a 
cell-surface receptor. Nature 325:733-736. 
Katzman R (1993) Education and the prevalence of dementia and Alzheimer's disease. Neurology 
43:13-20. 
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common 
structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 
300:486-489. 
Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, Abramowski D, Wiederhold 
KH, Sturchler-Pierrat C, Jucker M, Bergmann R, Staufenbiel M, Sommer B (2003) Progressive 
age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 
24:365-378. 
7. References 
                                    
 
74 
Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST (2003) 
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. Faseb J 
17:118-120. 
Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ (2001) The intracellular domain of the beta-
amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like 
manner. J Biol Chem 276:40288-40292. 
Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H (1988) Novel precursor of Alzheimer's 
disease amyloid protein shows protease inhibitory activity. Nature 331:530-532. 
Klafki HW, Wiltfang J, Staufenbiel M (1996) Electrophoretic separation of betaA4 peptides (1-40) and 
(1-42). Anal Biochem 237:24-29. 
Knopman D (2003) Alzheimer Type Dementia. In: Neurodegeneration: The molecular pathology of 
dementia and movement disorders (Dickson D, ed), pp 24-39. Basel: ISN Neuropath Press. 
Knopman DS, Ryberg S (1989) A verbal memory test with high predictive accuracy for dementia of 
the Alzheimer type. Arch Neurol 46:141-145. 
Knyihar-Csillik E, Csillik B, Oestreicher AB (1992) Light and electron microscopic localization of B-
50 (GAP43) in the rat spinal cord during transganglionic degenerative atrophy and 
regeneration. J Neurosci Res 32:93-109. 
Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, 
Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of 
deposited amyloid-beta peptides. Nat Med 10:719-726. 
Kokubo H, Kayed R, Glabe CG, Yamaguchi H (2005a) Soluble Abeta oligomers ultrastructurally 
localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease 
brain. Brain Res 1031:222-228. 
7. References 
                                    
 
75 
Kokubo H, Kayed R, Glabe CG, Saido TC, Iwata N, Helms JB, Yamaguchi H (2005b) Oligomeric 
proteins ultrastructurally localize to cell processes, especially to axon terminals with higher 
density, but not to lipid rafts in Tg2576 mouse brain. Brain Res 1045:224-228. 
Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic 
component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 
83:4044-4048. 
Lacor PN, Buniel MC, Klein WL (2004) ADDLs (Abeta oligomers) alter structure and function of 
synaptic spines. 2004 Abstract Viewer/Itinerary Planner:Program No. 218.213. 
Lamy C, Duyckaerts C, Delaere P, Payan C, Fermanian J, Poulain V, Hauw JJ (1989) Comparison of 
seven staining methods for senile plaques and neurofibrillary tangles in a prospective series of 
15 elderly patients. Neuropathol Appl Neurobiol 15:563-578. 
Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J, Chui H, Duara R, Foley 
EJ, Glatt SL, Green RC, Jones R, Karlinsky H, Kukull WA, Kurz A, Larson EB, Martelli K, 
Sadovnick AD, Volicer L, Waring SC, Growdon JH, Farrer LA (1996) Risk of dementia 
among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the 
oldest old? Neurology 46:641-650. 
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A 
specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357. 
Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager 
D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration 
in transgenic mice expressing mutant tau and APP. Science 293:1487-1491. 
Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN (2006) The Arctic Alzheimer 
mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in 
transgenic mice. Neurobiol Aging 27:67-77. 
Mandelkow EM, Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8:425-427. 
7. References 
                                    
 
76 
Martinez-Garcia F, Gonzalez-Hernandez T, Martinez-Millan L (1994) Pyramidal and nonpyramidal 
callosal cells in the striate cortex of the adult rat. J Comp Neurol 350:439-451. 
Masliah E, Mallory M, Ge N, Saitoh T (1992a) Amyloid precursor protein is localized in growing 
neurites of neonatal rat brain. Brain Res 593:323-328. 
Masliah E, Sisk A, Mallory M, Games D (2001) Neurofibrillary pathology in transgenic mice 
overexpressing V717F beta-amyloid precursor protein. J Neuropathol Exp Neurol 60:357-368. 
Masliah E, Mallory M, Hansen L, Alford M, DeTeresa R, Terry R, Baudier J, Saitoh T (1992b) 
Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting 
neurites in Alzheimer's disease. Brain Res 574:312-316. 
Masters CL, Beyreuther K (2003) Molecular Pathogenesis of Alzheimer's disease. In: 
Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (Dickson 
D, ed), pp 69-73. Basel: ISN Neuropath Press. 
Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985a) Neuronal origin 
of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein 
as the amyloid of plaque cores and blood vessels. Embo J 4:2757-2763. 
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985b) Amyloid 
plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 
82:4245-4249. 
Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1:120-129. 
Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, Chun M, Tycko B, Shelanski M 
(1995) Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients 
with Alzheimer's disease. Neurology 45:555-557. 
McCaddon A, Davies G, Hudson P, Tandy S, Cattell H (1998) Total serum homocysteine in senile 
dementia of Alzheimer type. Int J Geriatr Psychiatry 13:235-239. 
7. References 
                                    
 
77 
McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Activation of the classical complement 
pathway in brain tissue of Alzheimer patients. Neurosci Lett 107:341-346. 
McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, 
Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, 
Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition 
in mice. Neuron 47:191-199. 
Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, Hersh LB, Thiele DL 
(2003) Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity 
levels in vivo. Proc Natl Acad Sci U S A 100:6221-6226. 
Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute 
CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early phenotypic changes in 
transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol 
Chem 274:6483-6492. 
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, 
Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide 
vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-
985. 
Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, Nagao M, Fukuda H, Shimizu T, Shirasawa 
T (2004) Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic 
proline replacement. J Biol Chem 279:52781-52788. 
Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278:412-419. 
Mouton PR, Martin LJ, Calhoun ME, Dal Forno G, Price DL (1998) Cognitive decline strongly 
correlates with cortical atrophy in Alzheimer's dementia. Neurobiol Aging 19:371-377. 
Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, 
Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-
7. References 
                                    
 
78 
type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque 
formation. J Neurosci 20:4050-4058. 
Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity 
in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque 
amyloid in Creutzfeldt-Jakob disease. Brain Res 541:163-166. 
National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the 
Neuropathological Assessment of Alzheimer's Disease (1997) Consensus recommendations for 
the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 18:S1-2. 
Neve RL, Finch EA, Dawes LR (1988) Expression of the Alzheimer amyloid precursor gene 
transcripts in the human brain. Neuron 1:669-677. 
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of 
human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat 
Med 9:448-452. 
Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, 
Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arctic' APP mutation 
(E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 
4:887-893. 
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003a) Amyloid deposition precedes 
tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24:1063-
1070. 
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, 
Akbari Y, LaFerla FM (2003b) Triple-transgenic model of Alzheimer's disease with plaques 
and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409-421. 
7. References 
                                    
 
79 
Olichney JM, Hansen LA, Hofstetter CR, Lee JH, Katzman R, Thal LJ (2000) Association between 
severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a 
spurious one attributable to apolipoprotein E4. Arch Neurol 57:869-874. 
Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A (1995) 
Prevalence of Alzheimer's disease and vascular dementia: association with education. The 
Rotterdam study. Bmj 310:970-973. 
Petersen RC, Smith GE, Ivnik RJ, Kokmen E, Tangalos EG (1994) Memory function in very early 
Alzheimer's disease. Neurology 44:867-872. 
Phinney AL, Deller T, Stalder M, Calhoun ME, Frotscher M, Sommer B, Staufenbiel M, Jucker M 
(1999) Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in 
amyloid precursor protein transgenic mice. J Neurosci 19:8552-8559. 
Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of beta-amyloid protein 
causes peptide aggregation and neurotoxicity. Brain Res 563:311-314. 
Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) 
Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in 
cell culture. J Biol Chem 270:9564-9570. 
Ponte P, Gonzalez-DeWhitt P, Schilling J, Miller J, Hsu D, Greenberg B, Davis K, Wallace W, 
Lieberburg I, Fuller F (1988) A new A4 amyloid mRNA contains a domain homologous to 
serine proteinase inhibitors. Nature 331:525-527. 
Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related 
immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 
12:295-312. 
Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's 
disease: allelic variation and receptor interactions. Neuron 11:575-580. 
7. References 
                                    
 
80 
Reiner A, Veenman CL, Medina L, Jiao Y, Del Mar N, Honig MG (2000) Pathway tracing using 
biotinylated dextran amines. J Neurosci Methods 103:23-37. 
Roos RA, Haan J, Van Broeckhoven C (1991) Hereditary cerebral hemorrhage with amyloidosis--
Dutch type: a congophilic angiopathy. An overview. Ann N Y Acad Sci 640:155-160. 
Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF (2005) Soluble 
beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at 
glutamatergic synapses. J Neurosci 25:11061-11070. 
Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S (1996) Amino- and carboxyl-terminal 
heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 215:173-176. 
Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and 
differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile 
plaques. Neuron 14:457-466. 
Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E, Braak H (2000) Evolution of Alzheimer's 
disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol (Berl) 
100:259-269. 
Scheff SW, DeKosky ST, Price DA (1990) Quantitative assessment of cortical synaptic density in 
Alzheimer's disease. Neurobiol Aging 11:29-37. 
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, 
Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, 
Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) 
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP 
mouse. Nature 400:173-177. 
Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, 
Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA (2004) Hippocampal neuron loss 
7. References 
                                    
 
81 
exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 
164:1495-1502. 
Scholz W (1938) Studien zur Pathologie der Hirngefäße. II. Die drusige Entartung der Hirnarterien 
und -capillaren. (Eine Form seniler Gefäßerkrankung). Z ges Neurol Psychiatr 4:694-715. 
Schrader-Fischer G, Paganetti PA (1996) Effect of alkalizing agents on the processing of the beta-
amyloid precursor protein. Brain Res 716:91-100. 
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA 
(2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J 
Med 346:476-483. 
Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT 
(2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice 
demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25:7278-
7287. 
Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H (1999) 
Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar 
degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 155:1459-
1466. 
Staufenbiel M, Paganetti PA (1999) Electrophoretic Separation and Immunoblotting of Aβ1-40 and 
Aβ1-42. In: Methods in Molecular Medicine: Alzheimer's Disease: Methods and Protocols. 
Totowa, NJ: Humana Press Inc. 
Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer 
L, Davis KL (1994) A longitudinal study of Alzheimer's disease: measurement, rate, and 
predictors of cognitive deterioration. Am J Psychiatry 151:390-396. 
Stern Y, Tang MX, Denaro J, Mayeux R (1995) Increased risk of mortality in Alzheimer's disease 
patients with more advanced educational and occupational attainment. Ann Neurol 37:590-595. 
7. References 
                                    
 
82 
Storandt M, Botwinick J, Danziger WL, Berg L, Hughes CP (1984) Psychometric differentiation of 
mild senile dementia of the Alzheimer type. Arch Neurol 41:497-499. 
Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B (1992) Detection of interleukin-6 and alpha 
2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. 
Lab Invest 66:223-230. 
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, 
Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, 
Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer 
disease-like pathology. Proc Natl Acad Sci U S A 94:13287-13292. 
Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK (2004) 
Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured 
neurons and brain. J Neurosci 24:3592-3599. 
Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease 
inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's 
disease. Nature 331:528-530. 
Terry RD, DeTeresa R, Hansen LA (1987) Neocortical cell counts in normal human adult aging. Ann 
Neurol 21:530-539. 
Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS (1981) Some morphometric aspects of the 
brain in senile dementia of the Alzheimer type. Ann Neurol 10:184-192. 
Teter B, Ashford JW (2002) Neuroplasticity in Alzheimer's disease. J Neurosci Res 70:402-437. 
Thal DR, Schober R, Birkenmeier G (1997) The subunits of alpha2-macroglobulin receptor/low 
density lipoprotein receptor-related protein, native and transformed alpha2-macroglobulin and 
interleukin 6 in Alzheimer's disease. Brain Res 777:223-227. 
Thal DR, Del Tredici K, Braak H (2004) Neurodegeneration in Normal Brain Aging and Disease. Sci 
Aging Knowledge Environ in press. 
7. References 
                                    
 
83 
Thal DR, Rüb U, Orantes M, Braak H (2002a) Phases of Abeta-deposition in the human brain and its 
relevance for the development of AD. Neurology 58:1791-1800. 
Thal DR, Ghebremedhin E, Haass C, Schultz C (2002b) UV light-induced autofluorescence of full-
length Abeta-protein deposits in the human brain. Clin Neuropathol 21:35-40. 
Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H (2006a) The development of amyloid β-protein 
(Aβ)-deposits in the aged brain. Sci Aging Knowl Environ. 
Thal DR, Sassin I, Schultz C, Haass C, Braak E, Braak H (1999) Fleecy amyloid deposits in the 
internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments 
of Abeta. J Neuropathol Exp Neurol 58:210-216. 
Thal DR, Ghebremedhin E, Rüb U, Yamaguchi H, Del Tredici K, Braak H (2002c) Two types of 
sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61:282-293. 
Thal DR, Holzer M, Rüb U, Waldmann G, Gunzel S, Zedlick D, Schober R (2000a) Alzheimer-related 
tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and 
radiatum correlates with onset and degree of dementia. Exp Neurol 163:98-110. 
Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000b) 
Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp 
Neurol 59:733-748. 
Thal DR, Larionov S, Abramowski D, Wiederhold KH, Van Dooren T, Yamaguchi H, Haass C, Van 
Leuven F, Staufenbiel M, Capetillo-Zarate E (2006b) Occurrence and co-localization of 
amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and 
APP-transgenic mice. Neurobiol Aging. 
Thal DR, Capetillo-Zarate E, Schultz C, Rub U, Saido TC, Yamaguchi H, Haass C, Griffin WS, Del 
Tredici K, Braak H, Ghebremedhin E (2005) Apolipoprotein E co-localizes with newly formed 
amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of 
Abeta in a genotype-dependent manner. Acta Neuropathol (Berl) 110:459-471. 
7. References 
                                    
 
84 
Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto 
K, Younkin SG, Shoji M (2001a) Brain Abeta amyloidosis in APPsw mice induces 
accumulation of presenilin-1 and tau. J Pathol 194:500-506. 
Tomidokoro Y, Ishiguro K, Harigaya Y, Matsubara E, Ikeda M, Park JM, Yasutake K, Kawarabayashi 
T, Okamoto K, Shoji M (2001b) Abeta amyloidosis induces the initial stage of tau 
accumulation in APP(Sw) mice. Neurosci Lett 299:169-172. 
Tsai J, Grutzendler J, Duff K, Gan WB (2004) Fibrillar amyloid deposition leads to local synaptic 
abnormalities and breakage of neuronal branches. Nat Neurosci 7:1181-1183. 
Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003) Age-
dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 
17:388-396. 
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante 
P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, 
Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage 
of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. 
Science 286:735-741. 
Vetrivel KS, Thinakaran G (2006) Amyloidogenic processing of beta-amyloid precursor protein in 
intracellular compartments. Neurology 66:S69-73. 
Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J (1999) A stop-codon mutation 
in the BRI gene associated with familial British dementia. Nature 399:776-781. 
Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging 
brain. II. The distribution of amyloid vascular changes. Stroke 14:924-928. 
Virchow R (1854) Zur Cellulose-Frage. Virchows Arch Path Anat 6:416-426. 
Virchow R (1855) Veber den Gang der amyloiden Degeneration. Virchows Arch Path Anat 8:364-368. 
7. References 
                                    
 
85 
Voigt T, LeVay S, Stamnes MA (1988) Morphological and immunocytochemical observations on the 
visual callosal projections in the cat. J Comp Neurol 272:450-460. 
Wang D, Munoz DG (1995) Qualitative and quantitative differences in senile plaque dystrophic 
neurites of Alzheimer's disease and normal aged brain. J Neuropathol Exp Neurol 54:548-556. 
Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, 
Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term 
potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133-140. 
Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K (1989) 
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid 
protein. Cell 57:115-126. 
Weis S, Jellinger K, Wenger E (1991) Morphometry of the corpus callosum in normal aging and 
Alzheimer's disease. J Neural Transm Suppl 33:35-38. 
Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE (1998) Cerebral amyloid 
angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in 
Alzheimer's disease. Am J Pathol 153:725-733. 
Welsh K, Butters N, Hughes J, Mohs R, Heyman A (1991) Detection of abnormal memory decline in 
mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 
48:278-281. 
West MJ (1993) Regionally specific loss of neurons in the aging human hippocampus. Neurobiol 
Aging 14:287-293. 
West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal 
neuronal loss in normal ageing and Alzheimer's disease. Lancet 344:769-772. 
Wiederhold K-H, Staufenbiel M, Mistl C, Danner S (2004) Stages of amyloid deposition and plaque 
types in different APP transgenic mice as compared to AD (Abstract). Neurobiology of Aging 
25 Suppl. 2:254-255. 
7. References 
                                    
 
86 
Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, Haass C (1997) Intracellular 
generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol 
Chem 272:16085-16088. 
Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel 
M, Jucker M (2001) Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid 
angiopathy. J Neurosci 21:1619-1627. 
Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, 
Bayer TA (2001) Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid 
precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 306:116-120. 
Wise SP, Jones EG (1976) The organization and postnatal development of the commissural projection 
of the rat somatic sensory cortex. J Comp Neurol 168:313-343. 
Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J (1998) Diffuse, 
lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer 
disease. J Neuropathol Exp Neurol 57:674-683. 
Wouterlood FG (1993) Neuroscience Protocols: Elservier Science Publisher. 
Wu CC, Chawla F, Games D, Rydel RE, Freedman S, Schenk D, Young WG, Morrison JH, Bloom FE 
(2004) Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP 
mice: digital morphometric analyses. Proc Natl Acad Sci U S A 101:7141-7146. 
Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y (1998) Diffuse plaques associated with 
astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta 
Neuropathol (Berl) 95:217-222. 
Yamauchi H, Fukuyama H, Harada K, Nabatame H, Ogawa M, Ouchi Y, Kimura J, Konishi J (1993) 
Callosal atrophy parallels decreased cortical oxygen metabolism and neuropsychological 
impairment in Alzheimer's disease. Arch Neurol 50:1070-1074. 
7. References 
                                    
 
87 
Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, Qu GY, Grant I, Yu E, Levy P, et al. 
(1990) The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, 
gender, and education. Ann Neurol 27:428-437. 
Acknowledgments 
                                   
 
88 
ACKNOWLEDGMENTS 
 
I would like to express my gratitude to my supervisor, PD. Dr. med. D. R. Thal, for providing 
me with such an interesting topic, for the excellent supervision and support during this work.  
I wish to thank to all colleagues of the Institute of Neuropathology, especially to Prof. Dr. med. 
O. D. Wiestler and Prof. Dr. med. T. Pietsch for the opportunity to carry out this work in this institute. 
I wish to thank Prof. Dr. rer. nat. W. Kolanus, Prof. Dr. rer. nat. K. Willecke and P.D. Dr. rer. 
nat. G. van Echten-Deckert for the interest and time applied for the assessment of this work. 
I wish to thank all my co-authors, D. Abramowski, H. Braak, K. Del Tredici, A. Escher, E. 
Ghebremedhin, W. S. T. Griffin, C. Haass, S. Larionov, U. Rüb, T. C. Saido, C. Schultz, C. 
Stadelmann, M. Staufenbiel, T. Van Dooren, F. Van Leuven, K. H. Wiederhold and H. Yamaguchi for 
the valuable contribution to this work.  
I am very grateful to M. Staufenbiel and D. Abramoswski at the Novartis Institutes for 
Biomedical Research (Basel, Switzerland) for providing the animal models and performing the western 
blot and ELISA analysis; to C. Stadelmann and A. Escher at the Department of Neuropathology, 
Georg-August University (Göttingen, Germany) for providing the BDA traced samples; to C. Haass at 
the Department of Biochemistry, Adolf-Butenandt Institute, Ludwig Maximilians University  (Munich, 
Germany) and H. Yamaguchi at the Gunma University School of Health Sciences (Maebashi, Gunma, 
Japan) for the kind gift of the antibodies and to H. Braak at the Institute for Clinical Neuroanantomy, J. 
W. Goethe University (Frankfurt am Main, Germany) for providing some of the diagrams. 
I wish to thank Magdalena Sastre and Panagiotis Theofilas for the suggestions to improve the 
manuscript. 
I wish to thank all members of the group, it was a real pleasure to work and share this time with 
you all, and especially to Uta Enderlein and Nicole Kolosnjaji because without your help this work 
would not be possible, thanks.  
Acknowledgments 
                                   
 
89 
I wish also to thank H. U. Klatt for the excellent design and photographic work and to C. 
Kaschke for the work done with the 3D reconstructions of the DiI traced sections. 
During my time in Bonn I have made very good friends from Bulgaria, Greece, Germany, 
Spain, Tunisia, U.S.A. and other countries, my warmest thank to all of you for you help, support, for 
been available at any time, for the nice time we had and for the nice time we will have together.  
My special thanks to Ana A., Ana S. de O., Gaizka O., Iratxe D, Iratxe L. de A., Maider E. 
Orella G. de I. and Pablo O., because you are with me wherever I am. 
Finally, I will like to dedicate this work to my family because it means as much for them as it 
means for me. You have taught me that nothing is impossible, and with work, confidence and respect 
everybody can reach their objectives, thanks for supporting me always. 
 
 
 This study was supported by DFG-grant No. TH624/2 and BONFOR-grants No. O-154.0041, 
O-154.0068. 
 
 
 
Estibaliz Capetillo Gonzalez de Zarate
Erklarung/Declaration  
                                 
 
90 
ERKLÄRUNG/DECLARATION 
 
Hiermit versichere ich, dass diese Dissertation von mir persönlich, selbständig und ohne jede 
unerlaubte Hilfe angefertigt wurde. Die Daten, die im Rahmen einer Kooperation gewonnen wurden, 
sind ausnahmslos gekennzeichnet. Die vorliegende Arbeit wurde an keiner anderen Hochschule als 
Dissertation eingereicht. Ich habe früher noch keinen Promotionsversuch unternommen. Diese 
Dissertation wurde an der nachstehend aufgeführten Stelle auszugsweise veröffentlicht. 
 
Capetillo-Zarate, E.; Staufenbiel, M.; Abramowski, D.; Haass, C.; Escher, A.; Stadelmann, C.; 
Yamaguchi, H.; Wiestler, O.D.; Thal, D.R. (2006) Selective vulnerability of different types of 
commissural neurons for amyloid β-protein induced neurodegeneration in APP23 mice correlates with 
dendritic tree morphology. Brain, published online (DOI: 10.1093/brain/aw1176).  
Thal, D.R.; Capetillo-Zarate, E.; Del Tredici, K.; Braak, H. (2006) The development of amyloid β 
protein (Aβ)-deposits in the aged brain. Sci. Aging. Knowl.  Environ. Mar 8; (6): re1. 
 
 
Bonn, 09.11.2006 
 
 
Estibaliz Capetillo Gonzalez de Zarate 
 
List of Publications  
                                 
 
92 
LIST OF PUBLICATIONS 
 
 
Original articles 
Capetillo-Zarate, E.; Staufenbiel, M.; Abramowski, D.; Haass, C.; Escher, A.; Stadelmann, C.; 
Yamaguchi, H.; Wiestler, O.; Thal, D. (2006) Selective vulnerability of different types of 
commissural neurons for amyloid β-protein induced neurodegeneration in APP23 mice correlates with 
dendritic tree morphology.  Brain, in press, published online.  
 
Thal, D; Larionov, S.; Abramowski, D.; Wiederhold, K. H.; Van Dooren, T.; Yamaguchi, H.; 
Haass, C.; Van Leuven, F.; Staufenbiel, M.; Capetillo-Zarate, E. (2006) Occurrence and co-
localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type 
and APP-transgenic mice. Neurobiology of Aging, in press, published online. 
 
Thal, D.R.; Capetillo-Zarate, E.; Schultz, C.; Rüb, U.; Saido, T.C.; Yamaguchi, H.; Haass, C.; 
Griffin, W.S.T.; Del Tredici, K.; Braak, H.; Ghebremedhin, E. (2005) Apolipoprotein E co-
localizes with newly formed amyloid β-protein (Aβ)-deposits lacking immunoreactivity against N-
terminal epitopes of Aβ in a genotype-dependent manner. Acta Neuropathol (Berl). Nov; 110(5):459-
71. 
 
Reviews 
Thal, D.R.; Capetillo-Zarate, E.; Del Tredici, K.; Braak, H. (2006) The development of amyloid β-
protein (Aβ)-deposits in the aged brain. Sci. Aging. Knowl. Environ. Mar 8; (6): re1. 
 
 
 
 
 
